[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 230
1. Vassilopoulos G, Palassopoulou M, Zisaki K, Befani M, Bouronikou E, Giannakoulas N, Stathopoulou E, Matsouka P: Successful control of acute myelofibrosis with lenalidomide. Case Rep Med; 2010;2010:421239

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful control of acute myelofibrosis with lenalidomide.
  • Acute panmyelosis with myelofibrosis (APMF) is a rare, fatal hematological neoplasm that is characterized by the acute onset of cytopenias and fibrosis in the bone marrow in the absence of splenomegaly or fibrosis-related morphological changes in the RBCs.
  • We present the case of a 59-year-old female who presented with a two-month history of anemia, leucopenia and a normal platelet count.
  • At 4 months after diagnosis, the patient was started on Lenalidomide, 10 mg/day for a 21-d-course along with growth factor support.
  • To our knowledge, this is the first case for a medication that could reverse the fatal outcome of APMF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Aug 1;110(3):986-93 [17473062.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3495-503 [12393681.001]
  • [Cites] Br Med J. 1963 Aug 24;2(5355):472-7 [14043710.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Mod Pathol. 2005 May;18(5):603-14 [15578075.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1158-64 [16609064.001]
  • [Cites] Ann Hematol. 2004 Aug;83(8):513-21 [15173958.001]
  • (PMID = 21274282.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3026984
  •  go-up   go-down


2. Kar B, Nandhini B, Revathi R: Ring chromosome 8 and trisomy 8 in a patient with acute myeloid leukemia. Indian J Hematol Blood Transfus; 2009 Mar;25(1):30-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ring chromosome 8 and trisomy 8 in a patient with acute myeloid leukemia.
  • We describe a child with Acute Myeloid Leukemia (AML M7) with trisomy 8 and ring chromosome 8.
  • This 15-month-old girl had presented with a history of fever, weight loss of 1 kg, gum bleeds and pallor.
  • Clinical examinations revealed no nodes or organomegaly.
  • She developed acute myelofibrosis soon after the second cycle of chemotherapy with swinging fever and rapidly enlarging spleen.
  • She passed away on day 11 post transplantation of veno-occlusive disease of liver and multiorgan failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Pathol. 1992;6(3):161-7 [1429344.001]
  • [Cites] Cancer Genet Cytogenet. 1992 May;60(1):53-9 [1591707.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Nov;57(1):79-85 [1756488.001]
  • [Cites] Am J Hematol. 1997 Dec;56(4):224-9 [9395183.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1883-90 [8946926.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Dec;78(2):181-8 [7828151.001]
  • [Cites] Eur J Haematol. 1988 Oct;41(4):341-6 [3197821.001]
  • (PMID = 23100969.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453485
  • [Keywords] NOTNLM ; Acute myeloid leukemia / Ring chromosome 8 / Trisomy 8
  •  go-up   go-down


3. Orazi A, O'Malley DP, Jiang J, Vance GH, Thomas J, Czader M, Fang W, An C, Banks PM: Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol; 2005 May;18(5):603-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia.
  • The WHO criteria for diagnosing acute panmyelosis with myelofibrosis are somewhat distinct from those for acute megakaryoblastic leukemia.
  • However, clinical and hematopathologic findings partially overlap.
  • To determine the potential importance of bone marrow biopsy supplemented by immunohistochemistry in distinguishing between these two conditions, we studied 17 bone marrow biopsies of well-characterized cases of acute panmyelosis with myelofibrosis (six cases) and acute megakaryoblastic leukemia (11 cases).
  • Acute panmyelosis with myelofibrosis is characterized by a multilineage myeloid proliferation with a less numerous population of blasts than acute megakaryoblastic leukemia (P<0.01).
  • In the former condition, blasts are always positive with CD34, while in acute megakaryoblastic leukemia they express CD34 in 60% of the cases.
  • The blasts in acute panmyelosis with myelofibrosis only rarely express megakaryocytic antigens.
  • By contrast, acute megakaryoblastic leukemia has a significantly higher proportion of blasts expressing megakaryocytic antigens (P<0.01 with CD42b).
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Child. Child, Preschool. Chromosome Aberrations. Diagnosis, Differential. Female. Flow Cytometry. Humans. Karyotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578075.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


Advertisement
4. Takahashi N, Lee Y, Tsai DY, Ishii K, Kamio S: [Improvement of detection of early CT signs in hyperacute stroke using a novel noise reduction filter]. Nihon Hoshasen Gijutsu Gakkai Zasshi; 2008 Jul 20;64(7):881-2
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: In the diagnosis of hyperacute stroke, an early CT sign such as the loss of gray-white matter interface may be difficult to detect within the first hours of the onset of symptoms because of the presence of quantum noise on CT images.
  • METHODS AND MATERIALS: Our method provides an adaptive partial median filter (APMF), which can reduce local noise without blurring of anatomical structure using variable filter shape and size according to the pixel value distribution of object around a center pixel.
  • The APMF can enhance the loss of gray-white matter interface due to hyperacute stroke.
  • The CT images of 26 patients with acute (<5 hours) middle cerebral artery territory infarction were proved with follow-up CT.
  • The APMF was applied to all the CT images.
  • Four radiologists, without and with applying the APMF, indicated their confidence level regarding the presence (or absence) of the early CT signs on each CT images.
  • RESULTS: A 78% noise reduction with the APMF was obtained from simulation.
  • The average area under the ROC curve (Az) was improved from 0.868 to 0.924 for all radiologists by applying the APMF to the original images.
  • The difference in Az values with and without the APMF was statistically significant with a P value of .002 for all radiologists.
  • CONCLUSION: Our proposed APMF can improve the visibility of gray-white matter interface.
  • As a result, the APMF can help radiologists detect the early CT signs at emergency CT scan.
  • [MeSH-minor] Acute Disease. Chicago. Congresses as Topic. Humans. ROC Curve. Radiology. Societies, Medical

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719308.001).
  • [ISSN] 0369-4305
  • [Journal-full-title] Nihon Hōshasen Gijutsu Gakkai zasshi
  • [ISO-abbreviation] Nihon Hoshasen Gijutsu Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Orazi A, Czader MB: Myelodysplastic syndromes. Am J Clin Pathol; 2009 Aug;132(2):290-305
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Submitted cases highlighted important issues and difficulties in relation to the diagnosis and classification of MDS.
  • Much of the discussion focused on the correlation, or lack of it, between morphologic examination and other diagnostic techniques, cytogenetics in particular.
  • The cases included examples of isolated del(5q) chromosomal abnormality, including the "classical" 5q- syndrome and other myeloid neoplasms.
  • Particularly challenging is the correct identification of fibrotic subtypes of MDSs and their separation from subsets of acute myeloid leukemia with myelofibrosis such as acute panmyelosis with myelofibrosis.
  • At least for the foreseeable future, the diagnosis of MDS requires integration of morphologic, immunophenotypic, and genetic features in the light of patient history and clinical manifestations.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605823.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


6. Takahashi N, Lee Y, Tsai DY, Ishii K, Kinoshita T, Tamura H, Kimura M: Improvement of detection of hypoattenuation in acute ischemic stroke in unenhanced computed tomography using an adaptive smoothing filter. Acta Radiol; 2008 Sep;49(7):816-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of detection of hypoattenuation in acute ischemic stroke in unenhanced computed tomography using an adaptive smoothing filter.
  • PURPOSE: To evaluate the effect of a previously proposed adaptive smoothing filter for improving detection of parenchymal hypoattenuation of acute ischemic stroke on unenhanced CT images.
  • The adaptive partial median filter (APMF) designed for improving detectability of hypoattenuation areas on unenhanced CT images was applied.
  • Seven radiologists, including four certified radiologists and three radiology residents, indicated their confidence level regarding the presence (or absence) of hypoattenuation on CT images, first without and then with the APMF processed images.
  • Their performances without and with the APMF processed images were evaluated by receiver operating characteristic (ROC) analysis.
  • RESULTS: The mean areas under the ROC curves (AUC) for all observers increased from 0.875 to 0.929 (P = 0.002) when the radiologists observed with the APMF processed images.
  • The mean sensitivity in the detection of hypoattenuation significantly improved, from 69% (126 of 182 observations) to 89% (151 of 182 observations), when employing the APMF (P = 0.012).
  • The specificity, however, was unaffected by the APMF (P = 0.41).
  • CONCLUSION: The APMF has the potential to improve the detection of parenchymal hypoattenuation of acute ischemic stroke on unenhanced CT images.


7. Orazi A: Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology; 2007;74(2):97-114
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
  • In spite of the impressive advances in the area of molecular pathology, bone marrow morphology remains the diagnosis cornerstone to identify the various subtypes of myeloid neoplasms.
  • Immunohistochemistry of bone marrow biopsy with markers reactive in paraffin-embedded tissues represents a powerful diagnostic tool; its results can be easily correlated with those obtained by other techniques such as flow cytometry and genetic analysis, and above all, the clinical findings.
  • Particular emphasis is being given to the correct identification of cases of myeloid neoplasms associated with myelofibrosis and for which the bone marrow biopsy represents the only available diagnostic mean.
  • Such cases include two subtypes of acute myeloid leukemia which typically cause diagnostic difficulties: acute megakaryoblastic leukemia and acute panmyelosis with myelofibrosis (acute myelosclerosis).
  • Acute myeloid leukemia with multilineage dysplasia, therapy-related myelodysplastic syndrome/therapy-related acute myeloid leukemia and de novo myelodysplastic syndromes (MDS) will also be discussed.
  • In MDS, in particular, bone marrow biopsy may help in confirming a suspected diagnosis by excluding reactive conditions in which dyshematopoietic changes may also be observed.
  • In both of these variants, the presence of reticulin fibrosis or fatty changes in the bone marrow can make accurate disease characterization very difficult or impossible using bone marrow aspirates.
  • Finally, the important group of the myelodysplastic/myeloproliferative disorders can only be accurately categorized by a careful multiparametric approach in which the bone marrow biopsy exerts a pivotal role.
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid / diagnosis. Myelodysplastic Syndromes / diagnosis. Myeloproliferative Disorders / diagnosis
  • [MeSH-minor] Acute Disease. Antigens, CD34 / analysis. Antineoplastic Agents / adverse effects. Biopsy / methods. Diagnosis, Differential. Humans. Immunohistochemistry. Leukemia, Megakaryoblastic, Acute / diagnosis. Leukemia, Megakaryoblastic, Acute / pathology. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / pathology. Prognosis. Reticulin / analysis


8. Tolmachev AV, Monroe ME, Purvine SO, Moore RJ, Jaitly N, Adkins JN, Anderson GA, Smith RD: Characterization of strategies for obtaining confident identifications in bottom-up proteomics measurements using hybrid FTMS instruments. Anal Chem; 2008 Nov 15;80(22):8514-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An alternative strategy considered here, termed accurate precursor mass filter (APMF), employs linear ion trap (low resolution) MS/MS identifications generated by an appropriate search engine, such as SEQUEST, refined with high resolution precursor ion data obtained from FTMS mass spectra.
  • The APMF results can be additionally filtered using the LC elution time information from the AMT tag database, which constitutes a precursor mass and time filter (PMTF), the third approach implemented in this study.
  • Both the APMF and the PMTF approaches are evaluated for coverage and confidence of peptide identifications and contrasted with the AMT tag strategy.
  • Comparison of the AMT, APMF and PMTF approaches indicates that the AMT tag approach is preferential for studies desiring a highest achievable number of identified peptides.
  • In contrast, the APMF approach does not require an AMT tag database and provides a moderate level of peptide coverage combined with acceptable confidence values of approximately 99%.
  • Since AMT tag databases that exclude incorrect identifications are desirable, this study points to the value of a multipass APMF approach to generate AMT tag databases, which are then validated using the PMTF approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2008 Mar 15;80(6):2018-25 [18275164.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):960-8 [18205298.001]
  • [Cites] Bioinformatics. 2008 Apr 1;24(7):1021-3 [18304935.001]
  • [Cites] Anal Chem. 2008 Nov 15;80(22):8514-25 [18855412.001]
  • [Cites] J Am Soc Mass Spectrom. 2000 Apr;11(4):320-32 [10757168.001]
  • [Cites] Proteomics. 2002 May;2(5):513-23 [11987125.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Anal Chem. 2003 Mar 1;75(5):1039-48 [12641221.001]
  • [Cites] J Proteome Res. 2002 Jan-Feb;1(1):21-6 [12643522.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):621-6 [15253445.001]
  • [Cites] J Proteome Res. 2004 Jul-Aug;3(4):760-9 [15359729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13417-22 [15347803.001]
  • [Cites] Biotechniques. 2004 Oct;37(4):621-4, 626-33, 636 passim [15517975.001]
  • [Cites] OMICS. 2004 Fall;8(3):239-54 [15669716.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3120-30 [16038018.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):667-75 [16118637.001]
  • [Cites] Anal Chem. 2005 Nov 15;77(22):7246-54 [16285672.001]
  • [Cites] Anal Chem. 2005 Dec 1;77(23):7763-73 [16316187.001]
  • [Cites] Mass Spectrom Rev. 2006 May-Jun;25(3):450-82 [16429408.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):714-25 [16401633.001]
  • [Cites] J Microbiol Methods. 2006 Aug;66(2):223-33 [16417935.001]
  • [Cites] Genome Biol. 2006;7(5):R40 [16709260.001]
  • [Cites] Mol Cell Proteomics. 2006 Jul;5(7):1326-37 [16635985.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1927-41 [16857664.001]
  • [Cites] J Microbiol Methods. 2006 Dec;67(3):473-86 [16919344.001]
  • [Cites] Anal Chem. 2006 Nov 1;78(21):7397-409 [17073405.001]
  • [Cites] Anal Chem. 2006 Dec 15;78(24):8374-85 [17165830.001]
  • [Cites] Nat Methods. 2007 Mar;4(3):207-14 [17327847.001]
  • [Cites] Genome Res. 2007 Mar;17(3):328-36 [17255552.001]
  • [Cites] Mol Cell Proteomics. 2007 Mar;6(3):377-81 [17164402.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):2021-3 [17545182.001]
  • [Cites] Proteomics. 2007 Oct;7(19):3470-80 [17726677.001]
  • [Cites] Anal Chem. 2008 Feb 1;80(3):693-706 [18163597.001]
  • [Cites] Anal Chem. 2008 Feb 15;80(4):961-71 [18189369.001]
  • [Cites] Anal Chem. 2008 Mar 15;80(6):1871-82 [18271604.001]
  • (PMID = 18855412.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR018522; United States / NCRR NIH HHS / RR / RR 018522; United States / NCRR NIH HHS / RR / P41 RR018522-06; United States / NIGMS NIH HHS / GM / R01 GM063883; United States / NIAID NIH HHS / AI / Y1-AI-4894-01; United States / NCRR NIH HHS / RR / RR018522-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; EC 3.4.21.4 / Trypsin
  • [Other-IDs] NLM/ NIHMS112764; NLM/ PMC2692492
  •  go-up   go-down


9. Kreft A, Springer E, Lipka DB, Kirkpatrick CJ: Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. Acta Haematol; 2009;122(1):36-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
  • A 54-year-old female patient developed acute erythroleukemia after an 8-year course of primary myelofibrosis.
  • A bone marrow trephine biopsy disclosed 2 morphologically distinct areas of chronic primary myelofibrosis and acute erythroleukemia.
  • Although the activating JAK2-V617F mutation was not maintained in blasts of acute erythroleukemia, it was detectable in the chronic phase of primary myelofibrosis, indicating that this mutation did not play a role in the leukemic transformation of erythroid cells.
  • [MeSH-major] Janus Kinase 2 / genetics. Leukemia, Erythroblastic, Acute / genetics. Primary Myelofibrosis / complications. Primary Myelofibrosis / genetics

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel
  • (PMID = 19713696.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


10. Boruchov AM: Thrombocytopenia in myelodysplastic syndromes and myelofibrosis. Semin Hematol; 2009 Jan;46(1 Suppl 2):S37-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
  • Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoeisis and an increased risk of transforming to acute myelogenous leukemia (AML).
  • Determining the molecular basis of the disease has been hampered by its heterogeneity.
  • Treating the underlying disorder with a variety of differentiation and immunosuppressive agents alleviates the problem in a small percentage of patients but more often complicates the issue.
  • Primary myelofibrosis (MF) is a chronic myeloproliferative disorder associated with hepatosplenomegaly and refractory cytopenias.
  • However, there are currently no standard therapies to treat the thrombocytopenia that is often found in patients with this disease.
  • [MeSH-major] Myelodysplastic Syndromes / complications. Primary Myelofibrosis / complications. Thrombocytopenia / blood. Thrombocytopenia / etiology. Thrombocytopenia / therapy
  • [MeSH-minor] Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy


11. Naik SG, Negrin R, Laport G, Miklos D, Shizuru J, Arai S, Blume K, Wong R, Lowsky R, Johnston L: Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts were treated with a uniform preparatory regimen: busulfan 16.0 mg/kg (d-8 to-5), etoposide 60mg/kg (d-4), cyclophosphamide 60mg/kg (d-2), and graft-versus-host-disease (GVHD) prophylaxis of cyclosporine and prednisone.
  • Disease status at transplantation was induction failure (IF) acute myeloid leukemia (AML) (n = 10), HR AML in 1st complete remission (CR1) n = 11, in CR2 (n = 5), in CR3 (n = 2), relapsed refractory (RR) AML (n = 14), chronic myeloid leukemia (CML) in second chronic phase (n = 6), blast crisis (n = 2), myelofibrosis (n = 6), myeloproliferative disorders (n = 2), and MDS (n = 38).
  • With a median follow up of 5.6 yrs (1.6-14.6 yrs) actuarial 5-year overall survival (OS) was 32% (95% CI 22-42%) and 5-year probability for freedom from progression (FFP) was 64% (95% CI 52%-76%).
  • Cumulative incidence of acute (grade 3-4) and chronic GVHD was 28% (95% CI 19%-37%) and 38% (95% CI 24%-52%), respectively.
  • Relapse and acute GVHD remain significant causes of mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, Kho BC, Lee HK, Sim JP, Chan CH, Chan JC, Yeung YM, Law M, Liang R: Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med; 2005 Dec 12-26;165(22):2651-8
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.
  • BACKGROUND: Essential thrombocythemia (ET) is a clonal myeloproliferative disease associated with thrombohemorrhagic complications and myeloid transformation to diseases such as myelofibrosis and acute myeloid leukemia.
  • Thrombosis rates at and after diagnosis of ET were comparable to those of white patients, but bleeding rates at and after diagnosis were much lower.
  • There were no deaths among patients 60 years or younger during a maximum follow-up of 15 years, and splenomegaly at diagnosis of ET appeared to protect against thrombosis.
  • The probability of myelofibrosis transformation was 9.7% at 10 years.
  • Prior myelofibrosis (P = .008) and the use of melphalan treatment (P = .002) were risk factors for acute myeloid leukemia evolution.
  • CONCLUSIONS: Essential thrombocythemia is a benign disease of older persons.
  • Chinese patients have a low risk of bleeding, and prior myelofibrosis is a major risk factor for evolution to acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid / epidemiology. Primary Myelofibrosis / epidemiology. Thrombocythemia, Essential / mortality. Thrombosis / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Asian Continental Ancestry Group. Cell Transformation, Neoplastic. Female. Follow-Up Studies. Hong Kong / epidemiology. Humans. Hydroxyurea / therapeutic use. Male. Melphalan / therapeutic use. Middle Aged. Multivariate Analysis. Myeloablative Agonists / therapeutic use. Prognosis. Risk Factors. Sex Factors. Splenomegaly. Survival Analysis. beta-Thalassemia / epidemiology

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344424.001).
  • [ISSN] 0003-9926
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; Q41OR9510P / Melphalan; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


13. Elpek GO, Bozova S, Erdoğan G, Temizkan K, Oğüş M: Extramedullary hematopoiesis mimicking acute appendicitis: a rare complication of idiopathic myelofibrosis. Virchows Arch; 2006 Aug;449(2):258-61
MedlinePlus Health Information. consumer health - Appendicitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary hematopoiesis mimicking acute appendicitis: a rare complication of idiopathic myelofibrosis.
  • We report a case with a previous history of idiopathic myelofibrosis, which presented with clinical findings of acute appendicitis that necessitate appendectomy after the relief of his anemia.
  • The histopathological features of acute appendicitis were not observed.
  • Although in gastrointestinal system, obstruction and bleeding are the most common symptomatic manifestations, this case emphasizes that EMH might also present clinically as acute appendicitis.
  • The absence of histopathological features of acute appendicitis raises the possibility that local production of some mediators from hematopoietic precursor cells might contribute to this clinical presentation.
  • [MeSH-major] Appendicitis / diagnosis. Hematopoiesis, Extramedullary. Primary Myelofibrosis / complications
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16738896.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Fadilah SA, Raja-Zahratul-Azma RS, Leong CF: Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia. Malays J Pathol; 2006 Jun;28(1):55-8
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia.
  • Intense myelofibrosis is rarely associated with de novo acute myeloid leukaemia (AML) except in acute megakaryoblastic leukaemia (AML-M7) where there is diffuse marrow fibrosis as a consequence of proliferation of neoplastic myeloid cells.
  • AML associated with significant myelofibrosis developing both de novo or secondary to primary (idiopathic) myelofibrosis is characterised by a fulminant course and extremely poor prognosis, primarily due to treatment-resistant disease.
  • We describe a case of extensive myelofibrosis associated with acute erythroblastic leukaemia (AML-M6) that responded to induction therapy of the leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Erythroblastic, Acute / complications. Leukemia, Erythroblastic, Acute / drug therapy. Primary Myelofibrosis / complications. Primary Myelofibrosis / drug therapy
  • [MeSH-minor] Adult. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694960.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


15. Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R, Mahmud N, Finazzi G, Fruchtman SM, Popat U, Liu E, Prchal JT, Rondelli D, Barosi G, Hoffman R: The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood; 2005 Feb 15;105(4):1699-705
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.
  • Idiopathic myelofibrosis (IM) is characterized by the constitutive mobilization of CD34(+) cells.
  • G-CSF-mobilized CD34(+) cells produced multiple hematopoietic lineages within the NOD/SCID mice with a predominance of CD19(+) cells.
  • CD34(+) cells from one patient isolated prior to leukemic transformation were capable of generating acute leukemia in NOD/SCID mice.
  • In addition, the NOD/SCID model may be useful in gaining an understanding of the events occurring during the transition of IM to acute leukemia.
  • [MeSH-major] Bone Marrow Cells / pathology. Cell Movement. Hematopoiesis. Primary Myelofibrosis / blood. Primary Myelofibrosis / pathology
  • [MeSH-minor] Acute Disease. Animals. Antigens, CD34 / biosynthesis. Clone Cells. Female. Graft Survival / genetics. Graft Survival / immunology. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cells / immunology. Hematopoietic Stem Cells / pathology. Humans. Immunophenotyping. Leukemia / immunology. Male. Mice. Mice, Inbred NOD. Mice, SCID

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15471948.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


16. Charafeddine KM, Mahfouz RA, Zaatari GS, Ibrahim GY, Muwakkit SA, Najm ND, Farra CG: Essential thrombocythemia with myelofibrosis transformed into acute myeloid leukemia with der(1;15)(q10;q10): case report and literature review. Cancer Genet Cytogenet; 2010 Jul 1;200(1):28-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Essential thrombocythemia with myelofibrosis transformed into acute myeloid leukemia with der(1;15)(q10;q10): case report and literature review.
  • We herein report the first case in the literature, to our knowledge, of a 44-year-old female with essential thrombocythemia and severe myelofibrosis who developed acute myeloid leukemia (AML-M4) with der(1;15)(q10;q10) after 13 years of treatment.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 15. Leukemia, Myeloid, Acute / genetics. Primary Myelofibrosis / genetics. Thrombocythemia, Essential / genetics


17. Huang SC, Wu VC, Chou G, Huang TY, Lin SY, Sheu WH: Benign parathyroid adenoma presenting with unusual parathyroid crisis, anemia and myelofibrosis. J Formos Med Assoc; 2007 Feb;106(2 Suppl):S13-6
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign parathyroid adenoma presenting with unusual parathyroid crisis, anemia and myelofibrosis.
  • Although the clinical symptoms of patients with benign parathyroid adenoma are usually nonspecific and benign, a malignant presentation of the benign disease may sometimes occur.
  • Acute hypercalcemic crisis manifested and primary hyperparathyroidism was diagnosed together with myelofibrosis on account of the result of bone marrow biopsy.
  • These findings suggested that benign parathyroid adenoma may mimic the clinical presentation of parathyroid carcinoma, releasing excess parathyroid hormone and resulting in hyperparathyroid crisis.
  • In addition, primary hyperparathyroidism can be associated with anemia and myelofibrosis.

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493890.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


18. Shaheen SP 2nd, Talwalkar SS, Simons R, Yam L: Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature. Arch Pathol Lab Med; 2005 Jan;129(1):96-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature.
  • Leukemic transformation of chronic idiopathic myelofibrosis (CIMF) to acute lymphoblastic leukemia (ALL) is rare.
  • His disease eventually transformed to ALL of precursor B-cell type.
  • The simultaneous presentation of CIMF and PNH, complicated by the rare sequela of leukemic transformation, raises important issues with regard to diagnosis and treatment.
  • [MeSH-major] Hemoglobinuria, Paroxysmal / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Primary Myelofibrosis / complications
  • [MeSH-minor] Chronic Disease. Humans. Male. Middle Aged


19. Naoe T: Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies. Curr Pharm Biotechnol; 2006 Oct;7(5):331-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fusion genes involving ABL, ARG, PDGFRs, JAK2, SYK, TRKC, and FGFRs, and gain-of-function mutations of FLT3, KIT and JAK2 have been detected at various rates in myeloproliferative disease and acute myeloid leukemia.
  • Since the fusion or mutation of tyrosine kinase is a primary and central event in chronic myeloproliferative diseases, targeting the kinase activity has been thought to be an ideal intervention to treat these diseases.
  • The clinical success of imatinib for chronic myeloid leukemia has made this idea a reality, and has accelerated the development of new tyrosine kinase inhibitors (TKIs).
  • Challenging studies with TKIs have also been reported for acute myeloid leukemia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076649.001).
  • [ISSN] 1873-4316
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 111
  •  go-up   go-down


20. Lebwaze BM, Le Tourneau A, Rio B, Perrot JY, Heuberger L, Kabongo JM, Kalengayi RM, Molina T, Diebold J, Audouin J: [Histopathologic pattern of hyperplasia of bone marrow hematogones (medullar b lymphoid cell precursors) occurring after treatment of idiopathic myelofibrosis]. Ann Pathol; 2008 Feb;28(1):27-31
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathologic pattern of hyperplasia of bone marrow hematogones (medullar b lymphoid cell precursors) occurring after treatment of idiopathic myelofibrosis].
  • We report the case of a patient presenting idiopathic myelofibrosis with minimal myeloid blastic transformation causing severe pancytopenia, treated by allograft and showing in a bone marrow biopsy, a hyperplasia of B-lymphoid cells.
  • Histopathology and immunohistochemistry identified these cells as hyperplasia of hematogones and not a transformation into lymphoblastic acute leukaemia.
  • The cytology of a myelogram confirmed the diagnosis.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow / pathology. Hyperplasia / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Lymphocytes / pathology. Primary Myelofibrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538711.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R: Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res; 2010 Sep;34(9):1246-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic options for patients with myelofibrosis in blast phase.
  • Myelofibrosis (MF) is a clonal stem cell disorder with the potential to transform to acute leukemia, referred to as myelofibrosis in blast phase (MF-BP).
  • The outcome of patients with MF-BP is grave with a median survival of only 2.7 months.
  • MF-BP is largely refractory to conventional chemotherapy and intensive induction therapy fails to have a significant impact with a median survival of 3.9 months.
  • [MeSH-major] Primary Myelofibrosis / therapy

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • (PMID = 20627294.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Cvetković ZP, Cvetković BR, Celeketić D, Milenković D, Perunicić-Peković G: Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia. Acta Chir Iugosl; 2010;57(2):79-83
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia.
  • Extreme hiperuricaemia is seen in cancer patients with tumour lysis syndrome (TLS) which is classically associated with haematological malignancies with rapid tumour growth rates such as acute lymphoid leukaemia and high grade lymphomas.
  • Primary melofibrosis (Agnogenic myeloid metaplasia-AMM) is a chronic myeloproliferative disease characterized by splenomegaly, a leukoerythroblastic blood picture, teardrop poikilocytosis and varying degrees of marrow fibrosis.
  • In this paper we present a case of a 47-year-old male patient who was admitted to the hospital with symptoms of fatigue and small amount of urine, and clinical signs of plethora and enlarged spleen.
  • The bone marrow biopsy was also performed and histopathological diagnosis was: Hypercellulary phase of AMM.
  • [MeSH-major] Hyperuricemia / etiology. Primary Myelofibrosis / complications. Ureteral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20949707.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


23. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A: JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res; 2006 Nov;30(11):1457-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
  • Amongst 42 consecutive patients with leukemic transformation (LT) from myelofibrosis with myeloid metaplasia (MMM) 72% carried the JAK2(V617F) mutation.
  • The mutation was observed at expected frequencies in all subtypes of MMM and acute myeloid leukemia.
  • [MeSH-major] Janus Kinase 2 / genetics. Leukemia, Myeloid / genetics. Primary Myelofibrosis / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Substitution / genetics. Cytogenetic Analysis / methods. DNA / genetics. Disease Progression. Female. Humans. Male. Middle Aged. Mutation. Reverse Transcriptase Polymerase Chain Reaction / methods. Survival Rate

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563504.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 K23 CA96780-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


24. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, McQuaker G, Marks DI, Craddock C, McCann S, Russell N, Cook G, Kottaridis PD, British Society for Blood and Marrow Transplantation: The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant; 2010 Nov;45(11):1587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.
  • Fifty-one patients with primary myelofibrosis (PMF) received allogeneic haematopoietic stem cell transplants from related (n=33) or unrelated (n=18) donors.
  • Acute GVHD occurred in 29 and 38% of patients in the myeloablative and RIC groups, respectively.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation / methods. Primary Myelofibrosis / surgery

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154739.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ G0802523
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Kar R, Mahapatra M, Pati HP: PRCA with myelofibrosis: an unusual case report. Indian J Hematol Blood Transfus; 2008 Mar;24(1):26-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PRCA with myelofibrosis: an unusual case report.
  • The association of PRCA and myelofibrosis is very rare with only two such cases reported in the literature.
  • Leukemic transformation in myelofibrosis is known but the progression of PRCA to acute leukemia is very rare.
  • We present an unusual case of PRCA with myelofibrosis which after 14 months of transfusion dependent anemia transformed to acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nouv Presse Med. 1979 Nov 26;8(46):3817-20 [534248.001]
  • [Cites] Acta Haematol. 1991;85(3):124-7 [2042444.001]
  • [Cites] Medicine (Baltimore). 1986 Sep;65(5):339-51 [3091991.001]
  • [Cites] Br J Haematol. 1983 Mar;53(3):467-75 [6824588.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):8-12 [12508261.001]
  • [Cites] Blood. 2005 Feb 1;105(3):973-7 [15388582.001]
  • [Cites] J Int Med Res. 2005 Jul-Aug;33(4):460-6 [16104450.001]
  • [Cites] Blood. 1981 Nov;58(5):904-10 [6913410.001]
  • [Cites] Hematol Cell Ther. 1999 Feb;41(1):27-9 [10193643.001]
  • [Cites] Oncologist. 2004;9(3):247-58 [15169980.001]
  • (PMID = 23100937.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453159
  • [Keywords] NOTNLM ; Acute Leukemia / Myelofibrosis / PRCA
  •  go-up   go-down


26. Toubai T, Tanaka J, Higa T, Ota S, Ibata M, Shono Y, Mashiko S, Miura Y, Umehara S, Kahata K, Toyoshima N, Morioka M, Asaka M, Kasai M, Imamura M: Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities. Am J Hematol; 2005 Jan;78(1):67-70
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities.
  • A case of a leukemic transformation following a 27-year history of idiopathic myelofibrosis (IMF) is presented.
  • This patient's final diagnosis was acute micromegakaryocytic leukemia, and she died 1 month after leukemic transformation with an additional chromosomal abnormality, trisomy 8.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 13 / genetics. Primary Myelofibrosis / genetics
  • [MeSH-minor] Bone Marrow / pathology. Chromosomes, Human, Pair 8 / genetics. Fatal Outcome. Female. Follow-Up Studies. Gene Deletion. Humans. Leukemia, Megakaryoblastic, Acute / genetics. Middle Aged. Trisomy / genetics

  • Genetic Alliance. consumer health - Chromosome 11.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609290.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood; 2005 Feb 1;105(3):973-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
  • Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT).
  • All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%).
  • Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7.
  • Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%.
  • The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.
  • [MeSH-major] Leukemia / drug therapy. Leukemia / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Myelodysplastic Syndromes / pathology. Primary Myelofibrosis / pathology


28. Corella F, Barnadas MA, Bordes R, Curell R, Espinosa I, Vergara C, Alomar A: [A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis]. Actas Dermosifiliogr; 2008 May;99(4):297-300
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis].
  • [Transliterated title] Hematopoyesis extramedular cutánea en mielofibrosis idiopática: a propósito de un caso.
  • Cutaneous extramedullary hematopoiesis is a rare manifestation of chronic myeloproliferative processes, mainly chronic idiopathic myelofibrosis.
  • The lesions usually appear soon after diagnosis and the possibility of a relationship between splenectomy and the appearance of extramedullary foci of hematopoiesis is still debated.
  • Diagnosis is based on histopathology showing an infiltrate with different combinations of myeloid and erythroid cell precursors and megakaryocytes.
  • Symptomatic treatment is provided alongside treatment of the underlying disease.
  • We report a new case associated with chronic idiopathic myelofibrosis in which foci of cutaneous extramedullary hematopoiesis were observed 9 years after initial diagnosis.
  • The lesions were progressive and the patient went on to develop acute myeloid leukemia.
  • [MeSH-major] Hematopoiesis, Extramedullary. Primary Myelofibrosis / complications. Skin Physiological Phenomena

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394406.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP: JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood; 2005 Nov 15;106(10):3370-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
  • An activating 1849G>T mutation of JAK2 (Janus kinase 2) tyrosine kinase was recently described in chronic myeloproliferative disorders (MPDs).
  • The mutation was frequent in polycythemia vera (PV) (86%) and myelofibrosis (95%) but less prevalent in acute myeloid leukemia (AML) with an antecedent PV or myelofibrosis (5 [36%] of 14 patients).
  • No mutation was found in Ph(+)CML (99 patients), AML M0-M6 (28 patients), or acute lymphoblastic leukemia (20 patients).
  • We conclude that the JAK2 1849G>T mutation is common in Ph(-) MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Apr 10;280(1):103-10 [10805527.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1673-84 [12365015.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):601-5 [12708906.001]
  • [Cites] Cell. 1993 Jul 30;74(2):227-36 [8343951.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2535-40 [9326218.001]
  • [Cites] Cell. 1998 May 1;93(3):385-95 [9590173.001]
  • [Cites] Blood. 2005 Feb 1;105(3):973-7 [15388582.001]
  • [Cites] Curr Opin Hematol. 2005 Mar;12(2):112-6 [15725900.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2224-32 [15710945.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2662-7 [15805263.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1207-9 [15860661.001]
  • [Cites] Blood. 2002 Feb 1;99(3):840-9 [11806985.001]
  • (PMID = 16037387.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50CA100632
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC1895065
  •  go-up   go-down


30. Tamaki K, Otaka M, Sakamoto N, Matsumoto K, Yamashina S, Watanabe S: Acute variceal bleeding in a patient with idiopathic myelofibrosis successfully treated with endoscopic variceal band ligation and chemotherapy: a case report. J Med Case Rep; 2010;4:25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute variceal bleeding in a patient with idiopathic myelofibrosis successfully treated with endoscopic variceal band ligation and chemotherapy: a case report.
  • INTRODUCTION: Idiopathic myelofibrosis is a chronic myeloproliferative disorder characterized by leukoerythroblastosis, massive splenomegaly, and increases in the reticular and collagen fibers in the bone marrow.
  • Portal hypertension is observed in some patients with idiopathic myelofibrosis.
  • Gastrointestinal hemorrhages, which are due mostly to the rupture of the esophageal varices, have been sporadically reported to be an infrequent complication of idiopathic myelofibrosis.
  • CASE PRESENTATION: We report a case of a Japanese 63-year-old woman with myelofibrosis and variceal hemorrhage, with a background of concomitant portal and pulmonary hypertension.
  • CONCLUSION: This is the first known report on the successful application of endoscopic variceal ligation and chemotherapy as the therapeutic procedure for an esophageal variceal hemorrhage in a patient with myelofibrosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2007;46(4):187-90 [17301514.001]
  • [Cites] Ann Intern Med. 1962 Sep;57:419-40 [14478106.001]
  • [Cites] Am J Gastroenterol. 1965 Dec;44(6):536-44 [5891822.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):302-5 [2923095.001]
  • [Cites] Medicine (Baltimore). 1971 Sep;50(5):357-420 [4940717.001]
  • [Cites] J Gastroenterol. 1996 Apr;31(2):260-2 [8680548.001]
  • (PMID = 20181038.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2830976
  •  go-up   go-down


31. Jurisic V, Terzic T, Pavlovic S, Colovic N, Colovic M: Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. Pathol Res Pract; 2008;204(2):129-32
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis.
  • Myelofibrosis is a clonal myeloproliferative disorder characterized by splenomegaly, abnormal deposition of collagen in the bone marrow, extramedullary hematopoiesis, dacriocytosis, and leukoerythroblastic blood smear.
  • Osteosclerosis is the most frequently observed bone change in myelofibrosis.
  • Based on this, we present an atypical case of leukemic transformation in myelofibrosis associated with diffuse osteolytic lesions and extremely elevated TNF-alpha and lactate dehydrogenase (LDH).
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. L-Lactate Dehydrogenase / blood. Leukemia, Myeloid, Acute / blood. Osteolysis / blood. Parathyroid Hormone / blood. Primary Myelofibrosis / complications. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976926.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Tumor Necrosis Factor-alpha; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


32. Wakita S, Yamaguchi H, Okabe M, Takeuchi J, Tamai H, Nakamura K, Tajika K, Inokuchi K, Dan K: [Low dose whole lung irradiation for intractable pleural effusion due to idiopathic myelofibrosis]. Rinsho Ketsueki; 2006 Jun;47(6):526-30
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low dose whole lung irradiation for intractable pleural effusion due to idiopathic myelofibrosis].
  • A 63-year-old man with idiopathic myelofibrosis, diagnosed on Sept.
  • However, bilateral pleural effusion appeared only 2 weeks later, which was thought to be extramedullary hematopoiesis or acute transformation.
  • [MeSH-major] Hydroxyurea / therapeutic use. Lung / radiation effects. Pleural Effusion / radiotherapy. Primary Myelofibrosis / complications

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862981.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


33. Bai J, Xue Y, Ye L, Yao J, Zhou C, Shao Z, Qian L, Yang R, Li H, Zhang H, Zheng Y: Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China. Int J Hematol; 2008 Dec;88(5):530-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China.
  • To find out risk factors of incidences of long-term complications of thrombosis, myelofibrosis with myeloid metaplasia (MMM) and evolution into malignance in Chinese PV patients, we evaluated 320 PV patients referred to our center from April 1984 to June 2005 by Kaplan-Meier estimation and Cox proportional hazards models.
  • During the follow-up time, 11 and 2 patients died of fatal complications of thrombosis and acute myeloid leukaemia (AML), respectively.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Polycythemia Vera / mortality. Primary Myelofibrosis / mortality. Thromboembolism / mortality


34. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R, Myeloproliferative Diseases-Research Consortium: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood; 2005 May 15;105(10):4115-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.
  • A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen.
  • Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients.
  • There were 3 patients who died from acute GVHD, infection, and relapse.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Primary Myelofibrosis / complications. Primary Myelofibrosis / therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Female. Graft vs Host Disease / immunology. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Rate. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671439.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Amemiya S, Akahane M, Takita J, Igarashi T, Ohtomo K: Imaging findings of upper abdominal involvement by acute megakaryoblastic leukaemia. Pediatr Radiol; 2008 Apr;38(4):457-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings of upper abdominal involvement by acute megakaryoblastic leukaemia.
  • Acute megakaryoblastic leukaemia (AMKL), a relatively rare type of acute myeloid leukaemia, is characterized by frequent involvement of the liver, spleen and lymph nodes in addition to myelofibrosis in children.
  • Diagnosis is difficult both clinically and pathologically, and the hepatic or lymph node involvement is not uncommonly misinterpreted as solid tumour.
  • With the association of splenic lesion and lymphadenopathy, the imaging findings were considered indicative of a haematological disorder.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Fatal Outcome. Humans. Infant. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172635.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


36. Gangat N, Tefferi A: Pharmacotherapy of essential thrombocythemia. Expert Opin Pharmacother; 2008 Jul;9(10):1679-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The natural history of essential thrombocythemia is characterized by an increased incidence of thrombotic and hemorrhagic events and, in the long-term, a tendency for disease transformation to myelofibrosis or acute leukemia.
  • OBJECTIVE: The aim of this study was to outline the current evidence and the authors' opinion regarding the clinical management of patients with essential thrombocythemia.
  • RESULTS/CONCLUSIONS: Cytoreductive agents can reduce the rate of thrombotic events, but do not affect the overall survival or rate of disease transformation.
  • The management of intermediate-risk patients needs to be individualized: however, low-dose aspirin can be used after excluding acquired von Willebrand's disease.
  • [MeSH-minor] Age Factors. Antineoplastic Agents / therapeutic use. Aspirin / therapeutic use. Disease Progression. Humans. Hydroxyurea / therapeutic use. Interferon-alpha / therapeutic use. Janus Kinase 2 / antagonists & inhibitors. Risk Factors

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570601.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Platelet Aggregation Inhibitors; EC 2.7.10.2 / Janus Kinase 2; R16CO5Y76E / Aspirin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 51
  •  go-up   go-down


37. Barbui T, Finazzi G: Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost; 2007 Jun;33(4):321-9
Genetic Alliance. consumer health - Polycythemia vera.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical course of polycythemia vera (PV) and essential thrombocythemia (ET) is characterized by an increased incidence of thrombotic and hemorrhagic complications and an inherent tendency to progress into myelofibrosis or acute myeloid leukemia.
  • [MeSH-minor] Disease Management. Humans. Risk Assessment

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525889.001).
  • [ISSN] 0094-6176
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


38. Rain JD: [Polycythemia vera]. Rev Prat; 2005 Oct 15;55(15):1659-68
Genetic Alliance. consumer health - Polycythemia vera.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia vera (PV) is a chronic myeloproliferative disorder due to a haematopoietic stem cell's clonal proliferation.
  • This acquired disorder is often associated with thrombocytosis, leukocytosis and splenomegaly.
  • Generally, diagnosis remains easy, based on basic clinical and biological abnormalities.
  • Sometimes, positive diagnosis required more sophisticated tests as assay of endogenous erythroid colony, erythropoietin blood level and bone marrow biopsy.
  • Usually natural history of disease remains long with a good quality of life.
  • In some cases complications occur: mainly thrombosis and late myeloid metaplasia with myelofibrosis and acute leukemia.
  • Therapeutic approachs remain complex and difficult to optimize based up on age and disease severity.
  • [MeSH-major] Polycythemia Vera / diagnosis. Polycythemia Vera / drug therapy
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Erythroid Cells. Erythropoietin / blood. Humans. Leukemia / chemically induced. Leukemia / prevention & control. Quality of Life. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334202.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin
  • [Number-of-references] 16
  •  go-up   go-down


39. Bai J, Xue YP, Ye L, Yao JF, Zhou CL, Qian LS, Yang RC, Li HY, Zhang HY, Shao ZH: [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):685-8
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
  • OBJECTIVE: To reassess the natural history of polycythemia vera (PV) in Chinese and evaluate the relationship between the incidence of thrombosis, post-polycythaemic myelofibrosis with myeloid metaplasia( PPMM) , leukemia transformation and the therapeutic outcome and prognostic factors.
  • METHODS: The clinical manifestations, laboratory parameters and treatment were retrospectively analyzed in 287 patients with PV.
  • Most of these episodes occurred either at presentation or in the 2 years before diagnosis.
  • CONCLUSION: The incidence of thromboembolism is higher and the time to myelofibrosis was shorter in Chinese PV patients than in western PV patients.
  • [MeSH-major] Leukemia / etiology. Polycythemia Vera / complications. Primary Myelofibrosis / etiology. Thromboembolism / etiology
  • [MeSH-minor] Acute Disease. Female. Follow-Up Studies. Humans. Male. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399175.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD: Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood; 2008 Jan 15;111(2):767-75
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.
  • We discovered that Ts65Dn mice display persistent macrocytosis and develop a myeloproliferative disease (MPD) characterized by profound thrombocytosis, megakaryocyte hyperplasia, dysplastic megakaryocyte morphology, and myelofibrosis.
  • Of the 104 trisomic genes in Ts65Dn mice, Aml1/Runx1 attracts considerable attention as a candidate oncogene in DS-acute megakaryoblastic leukemia (DS-AMKL).
  • Surprisingly, trisomy for Aml1/Runx1 is not required for megakaryocyte hyperplasia and myelofibrosis, suggesting that trisomy for one or more of the remaining genes can promote this disease.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11598-602 [8524811.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):177-84 [7550346.001]
  • [Cites] Clin Genet. 1996 Jan;49(1):15-9 [8721566.001]
  • [Cites] Methods Mol Biol. 1997;68:53-76 [9055250.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):296-308 [10460585.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7596-602 [16140924.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):744-7 [16356423.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6224-9 [16603627.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):807-12 [16783379.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):65-75 [16843266.001]
  • [Cites] C R Biol. 2006 Sep;329(9):726-32 [16945839.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14146-51 [16966598.001]
  • [Cites] Mamm Genome. 2006 Oct;17(10):1005-12 [17019652.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2452-66 [17151367.001]
  • [Cites] Dev Dyn. 2000 Feb;217(2):137-45 [10706138.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):512-24 [10997960.001]
  • [Cites] Am J Med Genet. 2002 Feb 1;107(4):317-24 [11840489.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1617-20 [12747884.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4298-300 [12560215.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] Blood. 2004 Jan 15;103(2):399-406 [14512321.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1588-9 [15317736.001]
  • [Cites] Science. 2004 Oct 22;306(5696):687-90 [15499018.001]
  • [Cites] Cancer. 1990 May 15;65(10):2178-84 [2189548.001]
  • [Cites] Am J Med Genet. 1993 Jun 15;46(5):510-2 [8322810.001]
  • [Cites] Prog Clin Biol Res. 1993;384:117-33 [8115398.001]
  • [Cites] Blood. 1995 Jul 1;86(1):1-14 [7795214.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • (PMID = 17901249.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101774-06; United States / NCI NIH HHS / CA / R01 CA101774; United States / NCI NIH HHS / CA / R01 CA101774-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins; 0 / Runx1 protein, mouse
  • [Other-IDs] NLM/ PMC2200841
  •  go-up   go-down


41. Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation: Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol; 2007 Nov;35(11):1719-22
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
  • OBJECTIVE: To investigate the effect of a busulfan/fludarabine-based reduced intensity conditioning followed by allogeneic stem cell transplantation on regression of bone marrow fibrosis in patients with myelofibrosis.
  • METHODS: Twenty-four patients (male, n = 16; female, n = 8) with a median age of 52 years (range, 32-63 years) were included.
  • Diagnosis was primary myelofibrosis in 18 patients and secondary myelofibrosis in 6 patients; in 4 of them, primary myelofibrosis evolved from polycythemia vera, and in 2 of them from essential thrombocythemia.
  • No correlation between occurrence of acute graft-vs-host disease and fibrosis regression on day +180 was observed.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Primary Myelofibrosis / therapy
  • [MeSH-minor] Adult. Bone Marrow Examination. Busulfan / administration & dosage. Female. Graft vs Host Disease. Humans. Kinetics. Male. Middle Aged. Remission Induction / methods. Severity of Illness Index. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976523.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


42. Hélias C, Struski S, Gervais C, Leymarie V, Mauvieux L, Herbrecht R, Lessard M: Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet; 2008 Jan 1;180(1):51-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
  • Polycythemia vera (PV) is a clonal stem cell disorder characterized by an excessive erythrocyte production.
  • At diagnosis, a normal karyotype is found in < or =80% of cases, but an abnormal karyotype frequently develops with evolution.
  • Trisomy 9 and gains on 9p are some of the most frequent cytogenetic abnormalities, together with trisomy 8 and del(20q) in both PV and idiopathic myelofibrosis.
  • We report the case of a 54-year-old man whose disease was classified as an acute myeloid transformation of PV.
  • [MeSH-major] Gene Amplification. Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Polycythemia Vera / complications. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068534.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KDM4C protein, human; 0 / MLLT3 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / SMARCA2 protein, human; 0 / Transcription Factors; EC 1.14.11.- / Jumonji Domain-Containing Histone Demethylases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


43. Suzuki R, Onizuka M, Kojima M, Shimada M, Tsuboi K, Ogawa Y, Kawada H, Ando K: Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders. Tokai J Exp Clin Med; 2007 Dec;32(4):131-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
  • Wnt inhibitory factor-1 (WIF-1) is a negative regulator of Wnt signaling that is frequently downregulated by hypermethylation of the WIF-1 promoter in acute promyelocytic leukemia (APL) and other malignancies.
  • This is the first study to examine the relationship between WIF-1 methylation and the existence of JAK2V617F mutation in the pathogenesis of BCR/ABL-negative myeloproliferative disorders (MPD) including polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, and chronic myeloproliferative disease, unclassifiable.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Janus Kinase 2 / genetics. Myeloproliferative Disorders / enzymology. Myeloproliferative Disorders / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Chronic Disease. Cohort Studies. CpG Islands / genetics. Female. Fusion Proteins, bcr-abl. Humans. Male. Methylation. Middle Aged. Molecular Sequence Data. Mutation. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21318952.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Repressor Proteins; 0 / WIF1 protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


44. Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA, Groupe Francophone de Cytogénétique Hématologique: Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer; 2010 Oct;49(10):919-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
  • Evolution to myelofibrosis (MF), acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) may occur over time in myeloproliferative neoplasms (MPN) patients most likely due to the acquisition of additional mutations.
  • Significantly more -7/del(7q) (P = 0.004) and -5/del(5q) (P = 0.03) were found in AML/MDS with a higher incidence of dup1q (P = 0.01) in MF.
  • In multivariate analysis, two factors were independently associated with an inferior overall survival (OS); AML/MDS transformation (P < 0.0001) and -5/del(5q) abnormality (P = 0.02).
  • The mutated and wild-type forms of the genes were not found to be associated with a specific chromosomal abnormality.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629097.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


45. Adamus M: [Substance P as a regulatory peptide of hematopoiesis and blood cell functions]. Postepy Hig Med Dosw (Online); 2009 Mar 02;63:106-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SP seems to be important in the neoplastic transformation of bone marrow, leading to the development of acute leukaemia in children; myelofibrosis and also metastases to bone marrow of solid tumors in early stages of these diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252469.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Interleukin-3; 0 / Interleukin-6; 33507-63-0 / Substance P; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 87
  •  go-up   go-down


46. Ruan GR, Chen SS, Li LD, Liu YR, Qin YZ, Li JL, Ma X, Wang FR, Jiang Q, Jiang B, Liu KY, Huang XJ: [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe]. Zhonghua Yi Xue Za Zhi; 2007 Sep 11;87(34):2401-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
  • OBJECTIVE: To develop a novel platform for detection of the JAK2V617F mutation in patients with myeloproliferative disorders (MPD) by real-time quantitative PCR.
  • Peripheral blood samples were collected from 374 MPD patients, 76 with polycythemia vera (PV), 38 with chronic myelogenous leukemia (CML), and 115 with essential thrombocythemia (ET), and 19 with idiopathic myelofibrosis (IMF).
  • Peripheral blood samples from 65 patients with acute myelogenous leukemia (AML), 30 patients with acute lymphoblastic leukemia, 8 patients with chronic lymphoblastic leukemia, and 7 patients with non-Hodgkin's lymphoma and 16 cases of normal donor bone marrow were used as controls.
  • [MeSH-major] Janus Kinase 2 / genetics. Mutation. Myeloproliferative Disorders / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036317.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA Probes; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


47. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ, Navarro-Vázquez M, González-Carrillo ML: The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México. Rev Invest Clin; 2006 Sep-Oct;58(5):458-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new mutation (V617F) affecting the JAK2 gene has been recently described as acquired in patients with myeloproliferative disorders and other myeloid malignancies.
  • Using an amplification refractory mutation system, we investigated this mutation in 70 Mexican mestizo patients with hematological malignancies: 28 cases of acute lymphoblastic leukemia, 17 cases of Ph1-positive chronic myelogenous leukemia, 8 patients with acute myelogenous leukemia, 6 patients with chronic lymphocytic leukemia, 6 patients with polycythemia vera (PV), two patients with essential thrombocythemia (ET), one patient with hypereosinophilic syndrome one patient with primary myelofibrosis (MF) and one patient with chronic myelomonocytic leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408106.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


48. Brink DS: Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol; 2006 Sep;13(5):256-62
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
  • Transient leukemia of Down syndrome (DS-TL), also known as transient myeloproliferative disorder of Down syndrome (DS) and transient abnormal myelopoiesis of DS, occurs in approximately 10% of DS neonates and in phenotypically normal neonates with trisomy 21 mosaicism.
  • DS-TL neonates have a approximately 15% risk of developing potentially fatal liver disease and show <10% incidence of hydrops fetalis.
  • Additional manifestations of DS-TL include cutaneous involvement, hyperviscosity, myelofibrosis, cardiopulmonary failure, splenomegaly, and spleen necrosis.
  • Despite its typical transient nature, 20% to 30% of DS-TL patients develop overt (nontransient) acute leukemia, usually within 3 years and typically of the M7 phenotype (acute megakaryoblastic leukemia).
  • The pathogenesis of DS-TL (and of subsequent acute leukemia) involves mutation of GATA1 (on chromosome X), which normally encodes a transcription factor integral to normal development of erythroid, megakaryocytic, and basophilic/mast cell lines.
  • [MeSH-major] Down Syndrome / complications. Myeloproliferative Disorders / complications. Myeloproliferative Disorders / physiopathology

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998319.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 81
  •  go-up   go-down


49. Taki T, Taniwaki M: Chromosomal translocations in cancer and their relevance for therapy. Curr Opin Oncol; 2006 Jan;18(1):62-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Recurring chromosomal abnormalities are considered the primary genetic change in oncogenesis as well as an important indicator for tumor phenotype and clinical outcome.
  • Observation of high frequencies of mutations in NOTCH1, NPM and JAK2 in T-cell acute lymphoblastic leukemia, acute myeloid leukemia with normal karyotype and myeloproliferative disorders (polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis) have provided important suggestions for a better understanding of chromosomal translocations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357566.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oncogene Proteins, Fusion; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 46
  •  go-up   go-down


50. TAHARA K, YOKOHAMA A, HANDA H, SAITOH T, UCHIUMI H, SEKIGAMI T, TOYAMA K, MAWATARI M, OSAKI Y, MATSUSHIMA T, KARASAWA M, MURAKAMI H, TSUKAMOTO N, NOJIMA Y: Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera. Rinsho Ketsueki; 2009 Nov;50(11):1630-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
  • Ten years after being diagnosed with polycythemia vera, a 55-year-old woman required frequent blood transfusion due to secondary myelofibrosis.
  • At day 73, she developed acute graft-versus-host disease of the liver, while simultaneous resolution of splenomegaly occurred and complete donor chimerism in the peripheral blood was achieved.
  • Thus, RIST for an older patient with secondary myelofibrosis was successful without severe treatment-related morbidity.
  • This case suggests that RIST could be an effective treatment modality for secondary myelofibrosis.
  • [MeSH-major] Polycythemia Vera / complications. Primary Myelofibrosis / etiology. Primary Myelofibrosis / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Female. Graft vs Host Disease / prevention & control. Humans. Janus Kinase 2 / genetics. Melphalan / administration & dosage. Middle Aged. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009439.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


51. Neben-Wittich MA, Brown PD, Tefferi A: Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am J Hematol; 2010 Oct;85(10):808-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy.
  • Myelofibrosis (MF) is characterized by cytopenias/cytoses, leukoerythroblastic blood picture, bone marrow fibrosis, and extramedullary hematopoiesis.
  • No patients reported any acute or late side effects from radiation.Bone involvement in MF can cause disabling pain, but single-fraction low-dose radiation is a safe and effective treatment, often leading to a durable response.
  • [MeSH-major] Pain, Intractable / radiotherapy. Primary Myelofibrosis / complications

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799357.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


52. Ozbudak IH, Shilo K, Hale S, Aguilera NS, Galvin JR, Franks TJ: Alveolar airspace and pulmonary artery involvement by extramedullary hematopoiesis: a unique manifestation of myelofibrosis. Arch Pathol Lab Med; 2008 Jan;132(1):99-103
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar airspace and pulmonary artery involvement by extramedullary hematopoiesis: a unique manifestation of myelofibrosis.
  • Pulmonary extramedullary hematopoiesis is a rare manifestation of myelofibrosis.
  • Airspace foci were associated with acute and organizing alveolar hemorrhage, while within arteries the hematopoietic elements had a striking predilection for the vascular intima.
  • Extramedullary hematopoiesis should also be considered as a cause of pulmonary hemorrhage, especially in the setting of myelofibrosis.
  • [MeSH-major] Hematopoiesis, Extramedullary. Primary Myelofibrosis / pathology. Pulmonary Alveoli / pathology. Pulmonary Artery / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181682.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L, Groupe Francophone des Myelodysplasies (GFM): Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood; 2010 Nov 11;116(19):3735-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
  • Transformation of Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is associated with poor response to chemotherapy and short survival.
  • Fifty-four patients with Ph-negative MPN (including 21 essential thrombocythemia [ET], 21 polycythemia vera [PV], 7 primary myelofibrosis, and 5 unclassified MPN) who had progressed to AML (n = 26) or MDS (n = 28) were treated with azacitidine in a patient-named program.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / etiology. Myeloproliferative Disorders / complications. Myeloproliferative Disorders / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. France / epidemiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Philadelphia Chromosome. Prognosis. Treatment Outcome


54. Finazzi G, Harrison C: Essential thrombocythemia. Semin Hematol; 2005 Oct;42(4):230-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant progress in our understanding of the molecular pathogenesis of essential thrombocythemia (ET) and the other Philadelphia (Ph) chromosome-negative myeloproliferative disorders (MPDs) has recently been achieved.
  • Unfortunately, the diagnosis of ET still relies on a set of exclusion criteria developed years ago, as recent advances have yet to be evaluated for this purpose.
  • The clinical course of ET is characterized by an increased incidence of thrombotic and hemorrhagic complications and an inherent tendency to progress into myelofibrosis or acute myeloid leukemia (AML).
  • [MeSH-major] Pregnancy Complications, Hematologic / diagnosis. Pregnancy Complications, Hematologic / drug therapy. Thrombocythemia, Essential / diagnosis. Thrombocythemia, Essential / drug therapy

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210036.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


55. Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F, Vora N, Nakamura R, Forman SJ: Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant; 2010 Feb;16(2):281-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
  • Allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) regimens is a potentially curative treatment for patients (patients) with myelofibrosis (MF), as we and others have reported.
  • Nonrelapse mortality (NRM) from graft-versus-host disease (GVHD) and other complications has limited the success of this approach.
  • The probability of grade III or IV acute GVHD (aGVHD) was 60% for the CsA/MMF patients, and 10% for the tacrolimus/sirolimus group (P=.0102).

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Biol Blood Marrow Transplant. 2004 May;10(5):328-36 [15111932.001]
  • [Cites] Bone Marrow Transplant. 2009 Sep;44(5):317-20 [19234505.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2849-53 [15994287.001]
  • [Cites] Br J Haematol. 2006 Nov;135(3):367-73 [16972981.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Nov;12(11):1161-8 [17085309.001]
  • [Cites] Bone Marrow Transplant. 2006 Dec;38(11):721-7 [17013423.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2198-9 [17039230.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1 [17162218.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1316-21 [17018857.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Mar;13(3):355-65 [17317589.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3108-14 [17138818.001]
  • [Cites] Transplantation. 2007 Jun 15;83(11):1518-20 [17565328.001]
  • [Cites] Br J Haematol. 2008 Apr;141(1):80-3 [18324970.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):531-7 [18410895.001]
  • [Cites] Am J Hematol. 2008 Jun;83(6):491-7 [18429051.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6 [18640576.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Aug;14(8):942-3 [18640579.001]
  • [Cites] Haematologica. 2008 Oct;93(10):1514-22 [18728030.001]
  • [Cites] Haematologica. 2008 Oct;93(10):1449-50 [18827262.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1961-3 [18685610.001]
  • [Cites] Bone Marrow Transplant. 2008 Oct;42(8):567-8 [18660841.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4425-31 [18776081.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1):101-8 [19135948.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1866-8 [19228938.001]
  • [Cites] Am J Hematol. 2009 Mar;84(3):131-2 [19202548.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2895-901 [18988864.001]
  • [Cites] Eur J Haematol. 2009 May;82(5):329-38 [19141119.001]
  • [Cites] Blood. 2005 May 15;105(10):4115-9 [15671439.001]
  • (PMID = 19786111.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / P01 CA030206-160001; United States / NCI NIH HHS / CA / CA030206-160001; United States / NCI NIH HHS / CA / CA33572; United States / NCI NIH HHS / CA / CA033572-200003; United States / NCI NIH HHS / CA / P30 CA033572-200003; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P01 CA030206
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS148706; NLM/ PMC2819616
  •  go-up   go-down


56. Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR: Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood; 2010 Apr 08;115(14):2891-900
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
  • Acute myeloid leukemia (AML) may follow a JAK2-positive myeloproliferative neoplasm (MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2, remain obscure.
  • Primary myelofibrosis or myelofibrotic transformation preceded all 7 JAK2-mutant but only 1 of 9 JAK2 wild-type AMLs (P = .001), implying that JAK2-mutant AML is preceded by mutation(s) that give rise to a "myelofibrosis" phenotype.
  • [MeSH-major] Blast Crisis / genetics. Hematologic Neoplasms / genetics. Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Neoplasms, Second Primary / genetics. Primary Myelofibrosis / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Apr 8;115(14):2727-8 [20378759.001]
  • (PMID = 20008300.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0300497; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.3.2.27 / Proto-Oncogene Proteins c-cbl; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 6.3.2.- / CBL protein, human
  •  go-up   go-down


57. Nagata K, Shimoda K: [Myeloproliferative diseases caused by JAK2 mutation]. Rinsho Byori; 2009 Apr;57(4):357-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myeloproliferative diseases caused by JAK2 mutation].
  • Polycythemia vera (PV), essential thrombocythemia(ET), and primary myelofibrosis (PMF) share common clinical features, being clonal disorders of multipotent progenitors.
  • This may suggest that the expression levels of JAK2 V617F directly determine which cell lineages increase, possibly leading to the diversity of myeloproliferative diseases.
  • Although only V617F JAK2 may cause myeloproliferative disease (MPD), clonogenic assay, analysis of familial MPD patients, and examination of JAK2 mutation in acute leukemia patients transformed from MPD show that there are additional somatic mutations which contribute to the pathogenesis of V617F JAK2 positive PV, ET, and PMF.
  • [MeSH-major] Janus Kinase 2 / genetics. Janus Kinase 2 / physiology. Mutation. Myeloproliferative Disorders / genetics
  • [MeSH-minor] Humans. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology. Thrombocythemia, Essential / genetics. Thrombocythemia, Essential / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489438.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 22
  •  go-up   go-down


58. Ruiz-Argüelles GJ, Gomez-Almaguer D, Tarin-Arzaga LD, Morales-Toquero A, Cantu-Rodriguez OG, Manzano C: Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning. Rev Invest Clin; 2006 Jan-Feb;58(1):34-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight had a malignant condition (six acute leukemias, one myelofibrosis and one myelodysplasia), eleven individuals were allografted twice from the same donor and in one case, cells from two different umbilical cords were used.
  • Only three patients were successfully rescued with the second transplant, two with acute leukemia and one with aplastic anemia.
  • Seven patients are alive 10-41 months (median 35) after the second transplant, but only three (25%) remain disease-free.
  • [MeSH-minor] Acute Disease. Adult. Anemia, Aplastic / surgery. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Health Care Costs. Hospitals / statistics & numerical data. Hospitals, University / statistics & numerical data. Humans. Infant. Leukemia / surgery. Male. Mexico. Middle Aged. Neural Tube Defects / surgery. Osteopetrosis / surgery. Primary Myelofibrosis / surgery. Recurrence. Red-Cell Aplasia, Pure / surgery. Reoperation / statistics & numerical data. Survival Analysis. Thalassemia / surgery. Transplantation, Homologous / statistics & numerical data. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16789597.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


59. Murata J, Horii A, Tamura M, Mitani K, Mizuki M, Kubo T: Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. Acta Otolaryngol; 2006 May;126(5):548-52
Hazardous Substances Data Bank. ISOSORBIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She was also diagnosed as having a myelofibrosis with myeloid metaplasia (MMM).
  • Isosorbide, one of the osmotic diuretics commonly used for the treatment of Meniere's disease (MD) in Japan, was also effective in keeping her free from inner ear dysfunction.
  • We suppose that an immunological imbalance due to MMM, in conjunction with a specific immunogenetic background, may have played a role in the pathogenesis of RP and the formation of EH in this patient.
  • [MeSH-major] Ear Diseases / etiology. Ear, External. Endolymphatic Hydrops / complications. Hearing Loss, Sensorineural / etiology. Meniere Disease / etiology. Polychondritis, Relapsing / etiology
  • [MeSH-minor] Acute Disease. Audiometry, Evoked Response. Autoimmune Diseases / diagnosis. Autoimmune Diseases / drug therapy. Autoimmune Diseases / immunology. C-Reactive Protein / metabolism. Diagnosis, Differential. Diuretics, Osmotic / administration & dosage. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Humans. Immunoglobulin M / blood. Immunosuppressive Agents / administration & dosage. Isosorbide / administration & dosage. Middle Aged. Prednisone / administration & dosage. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / immunology. Thalidomide / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Relapsing polychondritis.
  • MedlinePlus Health Information. consumer health - Ear Disorders.
  • MedlinePlus Health Information. consumer health - Meniere's Disease.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698708.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Diuretics, Osmotic; 0 / Immunoglobulin M; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 9007-41-4 / C-Reactive Protein; VB0R961HZT / Prednisone; WXR179L51S / Isosorbide
  •  go-up   go-down


60. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR: Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol; 2005 Jan;74(1):47-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
  • OBJECTIVE: Acquired somatic point mutations in RUNX1/CBFA2/AML1 have recently been described in a subset of patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
  • Given the importance of core-binding factor in megakaryocytic differentiation and platelet production, as well as the central role of megakaryocytes in the pathophysiology of myelofibrosis with myeloid metaplasia (MMM), we hypothesised that RUNX1 gene mutations might be common in MMM.
  • In addition, it is unclear whether patients with MDS-associated acquired alpha thalassaemia (ATMDS), a special subgroup with a very high incidence of point mutations in the ATRX gene, have an especially high incidence of RUNX1 mutations.
  • [MeSH-major] DNA-Binding Proteins / genetics. Myelodysplastic Syndromes / genetics. Point Mutation. Primary Myelofibrosis / genetics. Proto-Oncogene Proteins / genetics. Transcription Factors / genetics


61. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, Ffrench M: Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res; 2008 Oct;32(10):1608-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
  • We report the emergence of a chronic myeloid leukaemia (CML) during the course of a JAK2V617F-positive chronic idiopathic myelofibrosis (CIMF) in the absence of any myelosuppressive treatment.
  • Although a response to imatinib was observed, the underlying myelofibrosis persisted after treatment and hydroxyurea was finally added to control the persistent thrombocytosis.
  • Moreover, the detection of BCR-ABL translocation appears to be crucial especially in the case of treated CIMF with an atypical course to identify CML before acute transformation.
  • [MeSH-major] Janus Kinase 2 / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Primary Myelofibrosis / complications
  • [MeSH-minor] Amino Acid Substitution. Chronic Disease. Fusion Proteins, bcr-abl / genetics. Humans. Male. Middle Aged. Point Mutation. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2008 Oct;32(10):1489-90 [18439674.001]
  • (PMID = 18448166.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


62. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G, Carroll M: A robust xenotransplantation model for acute myeloid leukemia. Leukemia; 2009 Nov;23(11):2109-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A robust xenotransplantation model for acute myeloid leukemia.
  • Xenotransplantation of human acute myeloid leukemia (AML) in immunocompromised animals has been critical for defining leukemic stem cells.
  • [MeSH-major] Disease Models, Animal. Leukemia, Myeloid, Acute / pathology. Mice, Inbred NOD. Neoplasm Transplantation / methods. Transplantation, Heterologous / methods
  • [MeSH-minor] Animals. Humans. Mice. Mice, SCID. Point Mutation. Primary Myelofibrosis / pathology. Receptors, Interleukin-2 / genetics. Severity of Illness Index. T-Lymphocytes, Cytotoxic / pathology. fms-Like Tyrosine Kinase 3 / genetics


63. Vannucchi AM, Guglielmelli P: Advances in understanding and management of polycythemia vera. Curr Opin Oncol; 2010 Nov;22(6):636-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Polycythemia vera is a relatively common myeloproliferative neoplasm (MPN) molecularly defined by the presence of mutations in the janus kinase (JAK2) gene.
  • Yet, many aspects of pathogenesis remain to be ascertained and no effective treatment for curing the disease or preventing major cardiovascular events and progression to myelofibrosis or acute leukemia exists.
  • Clinical trials with JAK2 inhibitors, either specific or not, have been initiated and first results are available.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805747.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


64. Barugola G, Cavallini A, Lipari G, Armatura G, Mantovani W, Baggio E: The role of splenectomy in myelofibrosis with myeloid metaplasia. Minerva Chir; 2010 Dec;65(6):619-25
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of splenectomy in myelofibrosis with myeloid metaplasia.
  • AIM: In this paper we retrospectively analyzed prospectively-collected data on our myelofibrosis with myeloid metaplasia (MMM) patients who underwent splenectomy.
  • Postoperative work-up consisting in laboratory tests and clinical evaluation performing a quality of life (QoL) test based on EORTC QLQ-C30 questionnaire.
  • Acute complications are almost exclusively limited to respiratory tract.
  • [MeSH-major] Primary Myelofibrosis / complications. Primary Myelofibrosis / surgery. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224796.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


65. Hemminki K, Sundquist J, Bermejo JL: Associated cancers in parents and offspring of polycythaemia vera and myelofibrosis patients. Br J Haematol; 2009 Nov;147(4):526-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associated cancers in parents and offspring of polycythaemia vera and myelofibrosis patients.
  • Polycythaemia vera (PV) and primary myelofibrosis (MF) show concordant familial clustering but limited population level data are available on the aggregation of other discordant neoplasms in these families.
  • Several discordant familial associations were found for PV (acute myeloid leukaemia, Hodgkin disease, prostate and bladder cancers) or for MF (chronic lymphatic leukaemia, colorectal, kidney and cervical cancers) or for both (nervous system, eye and endocrine tumours).
  • [MeSH-major] Polycythemia Vera / genetics. Primary Myelofibrosis / genetics
  • [MeSH-minor] Female. Genetic Predisposition to Disease. Humans. Male. Parents. Registries. Risk Assessment / methods. Siblings. Sweden / epidemiology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754924.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Liu ML, Kallakury B, Kessler C, Hartmann DP, Azumi N, Ozdemirli M: Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma. Leuk Lymphoma; 2006 Feb;47(2):315-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma.
  • Chronic idiopathic myelofibrosis (CIMF) is a chronic myeloproliferative disorder (CMPD) with progressive fibrosis and extramedullary hematopoiesis.
  • Similar to other CMPDs, the stem cell in CIMF has the potential to differentiate into myeloid or lymphoid lineages, and thus CIMF can culminate in acute leukemia of myeloid or, rarely, lymphoid lineage.
  • [MeSH-major] Hematopoiesis, Extramedullary. Plasmacytoma / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Chronic Disease. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Middle Aged. Spleen / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Plasmacytoma anaplastic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321864.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Okabayash S, Ohno C, Yasutomi Y: Acute megakaryocytic leukaemia (AMKL)-like disease in a cynomolgus monkey (Macaca fascicularis). J Comp Pathol; 2009 Feb-Apr;140(2-3):212-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute megakaryocytic leukaemia (AMKL)-like disease in a cynomolgus monkey (Macaca fascicularis).
  • A 5-year-old male cynomolgus monkey (Macaca fascicularis) with a clinical history of bleeding tendency, severe anaemia, thrombocytopenia and elevated serum concentration of liver-related enzymes was examined post mortem.
  • Microscopically, numerous atypical cells resembling myeloid cells were observed in the bone marrow, and myelofibrosis was present.
  • A diagnosis of acute megakaryocytic leukaemia (AMKL)-like disease was made.
  • This would appear to be the first report of AMKL-like disease in non-human primates.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Megakaryoblastic, Acute / veterinary. Monkey Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19159898.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Oyekunle A, Koehl U, Schieder H, Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N: CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy; 2006;8(4):375-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the results for eight patients (median age 46 years) transplanted initially for myelofibrosis, acute leukemia, myeloma and NHL.
  • No patient had developed acute or chronic GvHD.
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923613.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


69. Nikolousis E, Nagra S, Paneesha S, Delgado J, Holder K, Bratby L, Chaganti S, Lovell R, Milligan D: Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Ann Hematol; 2010 Nov;89(11):1141-5
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 105 patients had acute myeloid leukaemia, 83 had non-Hodgkin's lymphoma, three had myeloma, 21 had Hodgkin's lymphoma, 34 had acute lymphoblastic leukaemia, 19 had chronic myeloid leukaemia, 22 had chronic lymphocytic leukaemia, 24 had myelodysplasia, seven had T cell non-Hodgkin's lymphoma, six had aplastic leukaemia and seven had myelofibrosis.
  • Of the patients in the high and obese BMI group, 16% developed acute GvHD with 8% grade III-IV and 28% in the normal BMI group with 14% grade III-IV acute GvHD (p = 0.11).
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft vs Host Disease / drug therapy. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544351.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Thiele J, Kvasnicka HM: Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis? Curr Hematol Malig Rep; 2006 Jun;1(2):87-92
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significantly extending former descriptions of bone marrow features, a trilineage myeloproliferation (panmyelosis) with a pleomorphous appearance (differences in size) of megakaryopoiesis is a characteristic histopathologic finding in PV.
  • Advanced stages (spent phases) of PV show an increased left-shifted granulocytic proliferation accompanied by reduction of erythroid precursors and progressive myelofibrosis (postpolycythemic myeloid metaplasia).
  • [MeSH-major] Bone Marrow Cells / pathology. Bone Marrow Examination. Polycythemia / pathology. Polycythemia Vera / diagnosis
  • [MeSH-minor] Aged. Blast Crisis / pathology. Cell Lineage. Cohort Studies. Diagnosis, Differential. Disease Progression. Female. Fibrosis. Humans. Iron / analysis. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / pathology. Male. Middle Aged. Sensitivity and Specificity. Single-Blind Method. Stromal Cells / pathology. Thrombocythemia, Essential / diagnosis. Thrombocythemia, Essential / pathology. Unnecessary Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425337.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] E1UOL152H7 / Iron
  • [Number-of-references] 47
  •  go-up   go-down


71. Brière JB: Essential thrombocythemia. Orphanet J Rare Dis; 2007;2:3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage.
  • The median age at diagnosis is 65 to 70 years, but the disease may occur at any age.
  • The clinical picture is dominated by a predisposition to vascular occlusive events (involving the cerebrovascular, coronary and peripheral circulation) and hemorrhages.
  • Acute leukemia or myelodysplasia represent only rare and frequently later-onset events.
  • The molecular pathogenesis of ET, which leads to the overproduction of mature blood cells, is similar to that found in other clonal MPDs such as chronic myeloid leukemia, polycythemia vera and myelofibrosis with myeloid metaplasia of the spleen.
  • Polycythemia vera, myelofibrosis with myeloid metaplasia of the spleen and ET are generally associated under the common denomination of Philadelphia (Ph)-negative MPDs.
  • [MeSH-major] Thrombocythemia, Essential / diagnosis. Thrombocythemia, Essential / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Diagnosis, Differential. Disease Progression. Female. Hematologic Agents / therapeutic use. Humans. Incidence. Janus Kinase 2 / genetics. Male. Middle Aged. Mutation. Practice Guidelines as Topic. Pregnancy. Pregnancy Complications, Hematologic / diagnosis. Pregnancy Complications, Hematologic / therapy. Prevalence. Prognosis. Risk Assessment / methods. Sex Distribution. Sweden / epidemiology. Thrombocytosis / diagnosis

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1996 Jun;93(4):962-5 [8703834.001]
  • [Cites] Clin Lab Haematol. 1995 Sep;17(3):217-20 [8719893.001]
  • [Cites] Am J Hematol. 1996 Sep;53(1):6-10 [8813089.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;22 Suppl 1:15-29 [8951769.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;22 Suppl 1:31-40 [8951770.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):577-83 [10997967.001]
  • [Cites] Haematologica. 2000 Nov;85(11):1126-34 [11064463.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4261-6 [11110700.001]
  • [Cites] Mayo Clin Proc. 2001 Jan;76(1):22-8 [11155408.001]
  • [Cites] Br J Haematol. 2000 Dec;111(3):943-53 [11122159.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;22 Suppl 1:149-60 [8951786.001]
  • [Cites] Blood. 1997 Jan 1;89(1):128-34 [8978285.001]
  • [Cites] Semin Hematol. 1997 Jan;34(1):29-39 [9025160.001]
  • [Cites] Semin Hematol. 1997 Jan;34(1):51-4 [9025162.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):179-84 [9136963.001]
  • [Cites] Br J Haematol. 1997 May;97(2):453-6 [9163613.001]
  • [Cites] Semin Thromb Hemost. 1997;23(4):371-7 [9263354.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3370-7 [9345019.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4031-8 [9354672.001]
  • [Cites] Am J Hematol. 1997 Nov;56(3):168-72 [9371529.001]
  • [Cites] Blood. 1998 Jan 15;91(2):616-22 [9427717.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1091-6 [9694695.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):772-7 [9858229.001]
  • [Cites] Blood. 1999 Jan 15;93(2):417-24 [9885203.001]
  • [Cites] Leukemia. 1999 Feb;13(2):150-4 [10025886.001]
  • [Cites] Br J Haematol. 1999 Mar;104(4):929 [10192463.001]
  • [Cites] Ann Hematol. 1999 May;78(5):219-22 [10391102.001]
  • [Cites] Ann Hematol. 1999 Sep;78(9):389-92 [10525825.001]
  • [Cites] Am J Med. 2004 Nov 15;117(10):755-61 [15541325.001]
  • [Cites] Am J Obstet Gynecol. 2004 Dec;191(6):2016-20 [15592285.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):275-90 [15667529.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):583-92 [15725078.001]
  • [Cites] Leuk Res. 2005 May;29(5):481-91 [15755500.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Br J Haematol. 2005 May;129(3):293-306 [15842653.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Br J Haematol. 2005 May;129(4):553-60 [15877740.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] N Engl J Med. 2005 Jul 7;353(1):33-45 [16000354.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;22 Suppl 1:57-63 [8951773.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2037-40 [16709929.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2173-81 [16741247.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3548-55 [16873677.001]
  • [Cites] Leukemia. 2007 Feb;21(2):277-80 [17251900.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):47-53 [11918532.001]
  • [Cites] Thromb Haemost. 2002 May;87(5):802-7 [12038780.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1596-601 [12176877.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):786-90 [12181046.001]
  • [Cites] Am J Hematol. 2002 Sep;71(1):1-6 [12221665.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2078-83 [12357360.001]
  • [Cites] Ann Hematol. 2003 Mar;82(3):148-52 [12634946.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Jun;16(2):227-42 [12763489.001]
  • [Cites] Clin Appl Thromb Hemost. 1999 Apr;5(2):131-5 [10725994.001]
  • [Cites] Clin Appl Thromb Hemost. 1999 Oct;5(4):247-51 [10726022.001]
  • [Cites] Haematologica. 2000 May;85(5):492-5 [10800165.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):132-9 [10966175.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):153-65 [16029444.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1847-9 [16079890.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):208-13 [16197451.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2862-4 [15985544.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:201-8 [16304381.001]
  • [Cites] Lancet. 2005 Dec 3;366(9501):1945-53 [16325696.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):244-5 [16398659.001]
  • [Cites] Haematologica. 2006 Feb;91(2):169-75 [16461300.001]
  • [Cites] Blood. 2006 May 1;107(9):3676-82 [16373657.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32(3):171-3 [16673273.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32(3):174-207 [16673274.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32(3):219-30 [16673276.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32(3):231-45 [16673277.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32(3):246-50 [16673278.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32(3):251-9 [16673279.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4214-22 [16484586.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1181-3 [16598303.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2397-405 [16639737.001]
  • [Cites] Blood. 2006 Jul 1;108(1):346-52 [16537803.001]
  • [Cites] Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):381-98 [16810614.001]
  • [Cites] Ann Hematol. 1999 Oct;78(10):437-44 [10550553.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Hematol. 1999 Dec;78(12):539-43 [10647877.001]
  • [Cites] Ann Hematol. 2000 Jan;79(1):40-2 [10663620.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):100-9 [12833462.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1869-71 [12730106.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):26-31 [12949887.001]
  • [Cites] Haematologica. 2003 Oct;88(10):1130-8 [14555309.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:200-24 [14633783.001]
  • [Cites] N Engl J Med. 2004 Jan 8;350(2):114-24 [14711910.001]
  • [Cites] Haematologica. 2004 Feb;89(2):215-32 [15003898.001]
  • [Cites] Hematol J. 2004;5(2):161-7 [15048067.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):364-70 [15034760.001]
  • [Cites] Pathol Biol (Paris). 2004 Jun;52(5):267-74 [15217712.001]
  • [Cites] Ann Hematol. 2004 Aug;83(8):504-12 [15164229.001]
  • [Cites] Ann Hematol. 2004 Aug;83(8):495-7 [15175894.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):556-62 [2307991.001]
  • [Cites] Cancer. 1991 May 15;67(10):2658-63 [2015567.001]
  • [Cites] Br J Haematol. 1993 Feb;83(2):198-203 [8457467.001]
  • [Cites] Acta Haematol. 1994;91(2):84-8 [8023650.001]
  • [Cites] Ann Hematol. 2001 Feb;80(2):74-8 [11261328.001]
  • [Cites] Exp Hematol. 2001 Jun;29(6):670-6 [11378261.001]
  • [Cites] Br J Haematol. 2002 Mar;116(4):855-61 [11886392.001]
  • [Cites] Haematologica. 1993 Nov-Dec;78(6 Suppl 2):18-21 [8039753.001]
  • [Cites] N Engl J Med. 1995 Apr 27;332(17):1132-6 [7700286.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):748-56 [7772511.001]
  • (PMID = 17210076.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hematologic Agents; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 108
  • [Other-IDs] NLM/ PMC1781427
  •  go-up   go-down


72. Al-Ghazaly J, Al-Selwi AH, Abdullah M, Al-Jahafi AK, Al-Dubai W, Al-Hashdi A: Pattern of haematological diseases diagnosed by bone marrow examination in Yemen: a developing country experience. Clin Lab Haematol; 2006 Dec;28(6):376-81
MedlinePlus Health Information. consumer health - Blood Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 159 patients had Acute myeloid leukaemia, 75 had acute lymphocytic leukaemia, 87 had chronic myeloid leukaemia, 36 chronic lymphocytic leukaemia, eight had multiple myeloma, 13 myelodysplastic syndromes, seven myelofibrosis, seven polycythaemia vera, three primary thrombocythaemia, two hairy cell leukaemia, two metastases, 36 aplastic anaemia, 29 immune thrombocytopenic purpura (ITP), nine autoimmune haemolytic anaemia, three pernicious anaemia, 65 iron deficiency anaemia, 57 megaloblastic anaemia and malaria, 18 mixed deficiencies, and 11 patients had visceral leishmaniasis.
  • In conclusion, the leukaemias were the most frequently encountered diagnosis followed by iron deficiency anaemia, megaloblastic anaemia and malaria, aplastic anaemia and ITP respectively.
  • [MeSH-major] Hematologic Diseases / diagnosis. Hematologic Diseases / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105490.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulícek P, Campr V, Kren L, Penka M: Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost; 2006 Apr;32(3):231-45
Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
  • The rationale of the Czech Hematological Society guidelines for diagnosis and treatment of Philadelphia chromosome-negative myeloproliferative disorders with thrombocythemia (MPD-T) is reviewed.
  • For diagnosis of MPD-T, the classification according to the World Health Organization or to the Rotterdam criteria is preferred because they distinguish true essential thrombocythemia from prefibrotic or early fibrotic idiopathic myelofibrosis and prepolycythemic polycythemia vera.
  • The histopathology-based nosological distinction provided by these classifications yields valuable information on prognosis (including the risks of transition into secondary acute myeloid leukemia and myelofibrosis).
  • Another serious complication in MPD-T is thrombosis (arterial or venous), the main risk factors of which are age, previous thrombosis, platelet counts 350 to 2,200 x 10 (9)/L (peak at approximately 900 x 10 (9)/L) and the presence of additional thrombophilic risk factors (hereditary thrombophilia, any hypercoagulable state, cardiovascular disease).
  • [MeSH-major] Myeloproliferative Disorders / diagnosis. Practice Guidelines as Topic. Thrombocytosis / diagnosis
  • [MeSH-minor] Chronic Disease. Czechoslovakia. Humans. Risk Factors. Societies, Medical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673277.001).
  • [ISSN] 0094-6176
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander AR, Bacher U: Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol; 2009;122(4):185-92
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively analyzed outcomes of the second allo-SCT in 25 patients who received at least 2 allografts from related/unrelated donors due to relapse of acute myeloid leukemia, myelodysplastic syndrome or myelofibrosis after the first SCT.
  • A minority of the acute myeloid leukemia/myelodysplastic syndrome patients had reached complete hematological remission before the second SCT (6/25, 24%).
  • In conclusion, a second SCT offers the chance of stable remission for some patients relapsing with a myeloid malignancy after a first allo-SCT, although high treatment-related mortality and relapse rates remain a problem.
  • [MeSH-major] Leukemia, Myeloid, Acute / surgery. Myelodysplastic Syndromes / surgery. Peripheral Blood Stem Cell Transplantation. Primary Myelofibrosis / surgery
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Child, Preschool. Female. Graft Survival. Graft vs Host Disease / etiology. Humans. Leukemia, Myelomonocytic, Juvenile / surgery. Male. Middle Aged. Polycythemia / complications. Recurrence. Reoperation. Retrospective Studies. Salvage Therapy. Transplantation Conditioning. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19887774.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


75. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia; 2010 Sep;24(9):1574-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
  • We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, disease progression and survival in patients with polycythemia vera (PV).
  • During the study period, eight patients progressed to post-PV myelofibrosis (MF) (all carrying >50% mutant alleles), while 10 patients developed acute myeloid leukemia (AML).
  • The mutant allele burden was significantly related to the risk of developing myelofibrosis (P=0.029) and retained its significant effect also in multivariable analysis (P=0.03).
  • [MeSH-major] Alleles. Cell Transformation, Neoplastic / genetics. Janus Kinase 2 / genetics. Leukemia / genetics. Leukocytosis / genetics. Polycythemia Vera / genetics. Primary Myelofibrosis / genetics. Vascular Diseases / complications

  • Genetic Alliance. consumer health - Polycythemia vera.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631743.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


76. Hellmann A: Myeloproliferative syndromes: diagnosis and therapeutic options. Pol Arch Med Wewn; 2008 Dec;118(12):756-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloproliferative syndromes: diagnosis and therapeutic options.
  • Myeloproliferative syndromes (MPS) are clonal proliferation of hematopoietic progenitor cells characterized by proliferation of 1 or a few cell lines such as granulocytic, erythroid, megakaryocytic or mastocytic.
  • These syndromes include: chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, chronic neutrophilic leukemia and systemic mastocytosis.
  • Diagnosis of MPS is often difficult due to need of differential diagnosis with reactive proliferation caused by primarily non-hematological factors.
  • Differentiation of individual MPS forms is also difficult because of overlapping of particular clinical or laboratory adnormalities.
  • [MeSH-major] Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / therapy
  • [MeSH-minor] Bone Marrow. Diagnosis, Differential. Humans. Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Erythroblastic, Acute / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Neutrophilic, Chronic / diagnosis. Leukemia, Neutrophilic, Chronic / therapy. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / therapy. Risk Factors. Thrombocytosis / diagnosis. Thrombocytosis / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202955.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 19
  •  go-up   go-down


77. Mesa RA: Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program; 2007;:355-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.
  • The diagnosis and management of the BCR-ABL-negative myeloproliferative disorders (MPDs) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are at an explosive crossroads of scientific investigation and evolving paradigms since the discovery of the tyrosine kinase-activating JAK2V617F mutation in 2005.
  • No current medical therapy has altered the natural trend of the MPDs to lead to overt severe myelofibrosis or acute leukemia.
  • Specific inhibition of JAK2 itself appears promising by in vitro investigations, and clinical trials with multiple agents are planned to commence enrollment in 2007.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024651.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


78. Hemminki K, Zhang H, Sundquist J, Lorenzo Bermejo J: Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer. Breast Cancer Res Treat; 2008 Sep;111(1):165-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SIRs for subsequent neoplasms in women who had a family history of breast cancer were increased for ovarian (2.0) and endometrial (1.8) cancers and for acute lymphoid leukemia (12.7) and myelofibrosis (9.4).
  • The remarkably high risks for second acute lymphoid leukemia and myelofibrosis, both characterized by chromosomal aberrations, in women with a family history of breast cancer may signal heritable defects in the ability to process DNA damage caused by ionizing radiation and chemotherapy.
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Predisposition to Disease. Neoplasms, Second Primary / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899363.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Tefferi A: Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program; 2006;:240-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
  • JAK2V617F, a somatic gain-of-function mutation involving the JAK2 tyrosine kinase gene, occurs in nearly all patients with polycythemia vera (PV) but also in a variable proportion of patients with other myeloid disorders; mutational frequency is estimated at approximately 50% in both essential thrombocythemia (ET) and myelofibrosis (MF), up to 20% in certain subcategories of atypical myeloproliferative disorder (atypical MPD), less than 3% in de novo myelodysplastic syndrome (MDS) or acute myeloid leukemia, and 0% in chronic myeloid leukemia (CML).
  • Current information on disease-specific prognostic relevance of JAK2V617F is inconclusive and confounded by inter-study differences in the performance of mutation screening assays.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124067.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 41
  •  go-up   go-down


80. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood; 2006 Nov 15;108(10):3472-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
  • Recently, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM).
  • To gain more information on mutational frequency, disease specificity, and clinical correlates, genomic DNA from 1182 patients with myeloproliferative and other myeloid disorders and 64 healthy controls was screened for MPL515 mutations, regardless of JAK2V617F mutational status: 290 with MMM, 242 with polycythemia vera, 318 with essential thrombocythemia (ET), 88 with myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leukemia (AML).
  • The diagnosis of patients with mutant MPL alleles at the time of molecular testing was de novo MMM in 12 patients, ET in 4, post-ET MMM in 1, and MMM in blast crisis in 3.
  • Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease.
  • [MeSH-major] Janus Kinase 2 / genetics. Mutation, Missense. Myeloproliferative Disorders / genetics. Receptors, Thrombopoietin / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868251.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


81. Finazzi G, Gregg XT, Barbui T, Prchal JT: Idiopathic erythrocytosis and other non-clonal polycythemias. Best Pract Res Clin Haematol; 2006;19(3):471-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its diagnosis is based on the exclusion of polycythemia vera (PV), secondary acquired polycythemias and various congenital primary and secondary polycythemias.
  • IE is a stable disease with a low thrombotic risk and a low, if any, tendency to spontaneous progression to acute leukemia or myelofibrosis.
  • Myelosuppressive drugs should be avoided since their use is associated with evolution into acute leukemia in about 10% of patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781484.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 35
  •  go-up   go-down


82. Larghero J, Gervais N, Cassinat B, Rain JD, Schlageter MH, Padua RA, Chomienne C, Rousselot P: Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood; 2005 May 1;105(9):3743-5
Genetic Alliance. consumer health - Polycythemia vera.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia vera (PV) is an acquired myeloproliferative disorder with primary expansion of the red cell mass leading to an increased risk of thrombosis and less frequently to myelofibrosis and secondary acute leukemia.
  • Because long-term exposure to cytotoxic chemotherapy may increase the risk of acute transformation, new therapeutic options are needed.
  • Thus tipifarnib may specifically target PV stem cells and may be of clinical interest in the treatment of patients with PV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632209.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinolones; 11096-26-7 / Erythropoietin; 192185-72-1 / tipifarnib; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


83. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood; 2009 Dec 17;114(26):5264-70
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
  • From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70).
  • Acute graft-versus-host disease grade 2 to 4 occurred in 27% and chronic graft-versus-host disease in 43% of the patients.
  • Cumulative incidence of nonrelapse mortality at 1 year was 16% (95% confidence interval, 9%-23%) and significantly lower for patients with a completely matched donor (12% vs 38%; P = .003).
  • [MeSH-major] Primary Myelofibrosis / surgery. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Busulfan / therapeutic use. Disease-Free Survival. Female. Graft vs Host Disease / epidemiology. Humans. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Recurrence. Transplantation, Homologous. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812383.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00599547
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


84. Condat B, Valla D: Nonmalignant portal vein thrombosis in adults. Nat Clin Pract Gastroenterol Hepatol; 2006 Sep;3(9):505-15
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Portal vein thrombosis (PVT) consists of two different entities: acute PVT and chronic PVT.
  • Acute PVT usually presents as abdominal pain.
  • Chronic PVT is usually recognized after a fortuitous diagnosis of hypersplenism or portal hypertension, or when there are biliary symptoms related to portal cholangiopathy.
  • Local risk factors for PVT, such as an abdominal inflammatory focus, can be identified in 30% of patients with acute PVT; 70% of patients with acute and chronic PVT have a general risk factor for PVT, most commonly myeloproliferative disease.
  • Early initiation of anticoagulation therapy for acute PVT is associated with complete and partial success in 50% and 40% of patients, respectively.
  • A minimum of 6 months' anticoagulation therapy is recommended for the treatment of acute PVT.
  • Overall, the long-term outcome for patients with PVT is good, but is jeopardized by cholangiopathy and transformation of underlying myeloproliferative disease into myelofibrosis or acute leukemia.
  • [MeSH-minor] Adult. Clinical Trials as Topic. Humans. Hypertension, Portal / diagnosis. Hypertension, Portal / drug therapy. Hypertension, Portal / etiology. Risk Factors. Tomography, X-Ray Computed. Ultrasonography, Doppler, Color


85. O'Malley DP, Orazi A, Wang M, Cheng L: Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Mod Pathol; 2005 Dec;18(12):1562-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia.
  • Neoplastic myeloid proliferations are seen in the spleens of some patients with acute and chronic myeloproliferative disorders.
  • Both acute myeloid leukemia (AML) and chronic myeloproliferative disorders have a variety of underlying cytogenetic defects that can be evaluated by loss of heterozygosity (LOH) studies.
  • We evaluated the spleens in AML and chronic myeloproliferative disorders with neoplastic myeloid proliferations for the presence of LOH at several chromosome loci, and X-chromosome inactivation.
  • A total of 17 spleens were evaluated (chronic myelogenous leukemia = 6; chronic idiopathic myelofibrosis = 6; essential thrombocythemia = 1; AML arising from previous chronic myeloproliferative disorders = 4).
  • We examined LOH loci 7q (D7S2554), 8q (D8S263), 9p (D9S157, D9S161), 13q (D13S319), common sites of genetic abnormality in chronic myeloproliferative disorders, and TP53.
  • Our results show that allelic losses were common in the neoplastic extramedullary hematopoiesis found in spleens of chronic myeloproliferative disorders and AML.
  • [MeSH-major] Chromosomes, Human, X. Leukemia, Myeloid, Acute / genetics. Loss of Heterozygosity. Myeloproliferative Disorders / genetics. Spleen / pathology. X Chromosome Inactivation / genetics
  • [MeSH-minor] Bone Marrow Cells / pathology. Chronic Disease. Clone Cells. DNA, Neoplasm / analysis. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Microdissection. Polymerase Chain Reaction. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118625.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


86. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G: Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood; 2006 Feb 1;107(3):880-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
  • To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D.
  • The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies.
  • Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001).
  • These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human. Leukemia, Megakaryoblastic, Acute / mortality. Leukemia, Megakaryoblastic, Acute / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Neoplasms. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Primary Myelofibrosis / mortality. Primary Myelofibrosis / pathology. Primary Myelofibrosis / therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123215.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kennedy JA, Barabé F, Patterson BJ, Bayani J, Squire JA, Barber DL, Dick JE: Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci U S A; 2006 Nov 7;103(45):16930-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.
  • Activation of JAK2 by chromosomal translocation or point mutation is a recurrent event in hematopoietic malignancies, including acute leukemias and myeloproliferative disorders.
  • Here we report that expression of TEL-JAK2, a constitutively active variant of the JAK2 kinase, in lineage-depleted human umbilical cord blood cells results in erythropoietin-independent erythroid differentiation in vitro and induces the rapid development of myelofibrosis in an in vivo NOD/SCID xenotransplantation assay.
  • These studies provide functional evidence that activated JAK2 signaling in primitive human hematopoietic cells is sufficient to drive key processes implicated in the pathophysiology of polycythemia vera and idiopathic myelofibrosis.
  • Furthermore, they describe an in vivo model of myelofibrosis initiated with primary cells, highlighting the utility of the NOD/SCID xenotransplant system for the development of experimental models of human hematopoietic malignancies.
  • [MeSH-major] Erythropoiesis / physiology. Hematopoietic Stem Cells / metabolism. Oncogene Proteins, Fusion / metabolism. Primary Myelofibrosis / etiology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2076-83 [10706877.001]
  • [Cites] Blood. 2002 May 1;99(9):3197-204 [11964283.001]
  • [Cites] Nat Immunol. 2001 Jan;2(1):75-82 [11135582.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1438-48 [12149229.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3495-503 [12393681.001]
  • [Cites] Nat Med. 2003 Jul;9(7):959-63 [12796774.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):952-9 [14737125.001]
  • [Cites] Exp Hematol. 2004 Feb;32(2):179-87 [15102479.001]
  • [Cites] J Exp Med. 2004 Sep 6;200(5):623-35 [15353555.001]
  • [Cites] N Engl J Med. 1974 Jun 13;290(24):1382 [4827655.001]
  • [Cites] Hum Mol Genet. 1995 Feb;4(2):163-72 [7757063.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2535-40 [9326218.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8239-44 [9653171.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5321-33 [9736611.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4354-64 [10361134.001]
  • [Cites] Genome Biol. 2004;5(12):253 [15575979.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):265-72 [15621811.001]
  • [Cites] Leukemia. 2005 Mar;19(3):442-8 [15674417.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2662-7 [15805263.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1259-61 [15878972.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1692-6 [16034466.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):329-33 [16001431.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14398-403 [16172394.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1148-51 [16226118.001]
  • [Cites] Oncogene. 2005 Nov 3;24(48):7248-52 [16091753.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7 [16365288.001]
  • [Cites] Leukemia. 2006 Mar;20(3):536-7 [16424865.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):500; author reply 500-2 [16564930.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4274-81 [16478879.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1652-60 [16670266.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1551-4 [16684963.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2286-92 [11290589.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):32704-13 [11435425.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):693-704 [11030348.001]
  • (PMID = 17077140.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Recombinant Proteins; 0 / TEL-JAK2 fusion protein, human; 11096-26-7 / Erythropoietin
  • [Other-IDs] NLM/ PMC1629449
  •  go-up   go-down


88. Levine RL, Heaney M: New advances in the pathogenesis and therapy of essential thrombocythemia. Hematology Am Soc Hematol Educ Program; 2008;:76-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Essential thrombocythemia (ET) is a hematopoietic disorder that manifests clinically as thrombocytosis, and patients with ET are at increased risk for developing thrombosis, myelofibrosis, and transformation to acute myeloid leukemia.
  • Although ET was recognized as a distinct clinical syndrome more than 6 decades ago and was classified as a myeloproliferative neoplasm (MPN) by William Dameshek in 1951, the molecular pathogenesis of ET remained unknown until 2005, when activating mutations in the JAK2 tyrosine kinase (JAK2V617F) were identified in a significant proportion of patients with ET, polycythemia vera (PV) and primary myelofibrosis (PMF).

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074062.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptors, Thrombopoietin; EC 1.1.1.49 / Glucosephosphate Dehydrogenase; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 67
  •  go-up   go-down


89. Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C, French Group of Familial Myeloproliferative Disorders: Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood; 2009 Aug 20;114(8):1628-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
  • The JAK2(V617F) mutation does not elucidate the phenotypic variability observed in myeloproliferative neoplasm (MPN) families.
  • In a patient with 2 TET2 mutations, the analysis of 5 blood samples at different phases of her disease showed the sequential occurrence of JAK2(V617F) and TET2 mutations concomitantly to the disease evolution.
  • TET2 mutations were mainly observed (10 of 12) in patients with primary myelofibrosis or patients with polycythemia vera or essential thrombocythemia who secondarily evolved toward myelofibrosis or acute myeloid leukemia.
  • [MeSH-major] Bone Marrow Neoplasms / genetics. DNA-Binding Proteins / genetics. Myeloproliferative Disorders / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Cells, Cultured. DNA Mutational Analysis. Family. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Phenotype


90. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, Zilberman I, Miron S, Leubovic A, Slavin S, Or R: Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant; 2005 Dec;36(12):1097-101
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.
  • We evaluated the effect of alefacept (Amevive), a novel dimeric fusion protein, in steroid resistant/dependent acute graft-versus-host-disease (aGVHD).
  • Skin GVHD responded rapidly with a median of 1 day to IR and 7 days to CR.
  • [MeSH-major] Drug Resistance. Graft vs Host Disease / drug therapy. Recombinant Fusion Proteins / therapeutic use. Steroids / pharmacology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bone Marrow Transplantation. Child. Female. Gastrointestinal Tract / pathology. Humans. Infection. Liver / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Primary Myelofibrosis / therapy. Skin / pathology. Skin Abnormalities / therapy. T-Lymphocytes / metabolism. Time Factors. Transplantation Conditioning. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247429.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Steroids; ELK3V90G6C / alefacept
  •  go-up   go-down


91. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood; 2005 Nov 15;106(10):3377-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
  • Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
  • We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL).
  • We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45).
  • These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.


92. Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A: Treatment options for essential thrombocythemia and polycythemia vera. Expert Rev Hematol; 2009 Feb;2(1):41-55
Genetic Alliance. consumer health - Polycythemia vera.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this article.
  • Major causes of morbidity and mortality are represented by arterial and venous thrombosis, as well as by evolution to myelofibrosis or transformation to acute leukemia.
  • However, results of clinical trials with interferon, and the expected effects of novel drugs selectively targeting the abnormal pathways that are involved in the clonal myeloproliferation, are pushing therapeutic goals from disease control only to cure.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082994.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


93. Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, Tefferi A: Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Eur J Haematol; 2010 Mar;84(3):191-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
  • Although occasionally seen in chronic phase MPN, unbalanced 1;7 translocations, e.g. der(1;7)(q10;p10), are usually seen in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and post-MPN AML/MDS.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1. Leukemia, Myeloid / genetics. Myelodysplastic Syndromes / genetics. Myeloproliferative Disorders / genetics

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002154.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


94. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol; 2005 Apr 1;23(10):2224-32
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The clinical course of polycythemia vera is often complicated by thrombosis as well as by the possible transition to myeloid metaplasia with myelofibrosis or acute myeloid leukemia.
  • PATIENTS AND METHODS: Overall, 1,638 patients from 12 countries were enrolled onto a large, prospective multicenter project aimed at describing the clinical history of polycythemia vera for the following outcomes: survival, the cumulative rate of cardiovascular death and thrombosis, the cumulative rate of leukemia, myelodysplasia, and myelofibrosis.
  • The mean duration of the disease at entry and the duration of the follow-up were 4.9 and 2.7 years, respectively.
  • Antiplatelet therapy, but not cytoreductive treatment, was significantly associated with a lower risk of cardiovascular events.
  • We found a consistent association between age and risk of leukemia, and between duration of the disease with risk of myelofibrosis.
  • The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Petrides PE: [Primary thrombocythemia: diagnosis and therapy]. Med Klin (Munich); 2006 Aug 15;101(8):624-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary thrombocythemia: diagnosis and therapy].
  • BACKGROUND: Primary thrombocythemia is a rare acquired chronic disorder of the bone marrow which can occur at any age.
  • Diagnosis is based upon elevated platelet counts, morphologically and functionally altered platelets and characteristic bone marrow alterations as well as the exclusion of related myeloproliferative disorders which can also be accompanied by increased platelet counts.
  • Possible disease complications are thromboembolic and hemorrhagic events as well as a transformation into myelofibrosis or acute leukemia.
  • Inhibition of platelet aggregation with aspirin for the prevention of thromboembolic complications is first-line therapy; cytoreductive therapy with drugs such as hydroxyurea or interferon-alpha or thromboreductive therapy with the platelet-reducing agent anagrelide is required when thromboembolic complications are already present at diagnosis (secondary prevention) or when platelet counts are steadily increasing or various additional risk factors are present (primary prevention).
  • In up to 50% of the patients the recently discovered V617F mutation in the JAK2 gene can be identified which is supposed to be involved in the pathogenesis of this disease.
  • CLINICAL STUDIES: Because of the rarity of primary thrombocythemia thus far only two prospectively randomized studies have been carried out to compare cyto- and thromboreductive therapies.
  • CONCLUSION: Due to the existence of randomized clinical studies expert opinion will, in the future, be increasingly replaced by evidence-based therapy guidelines.
  • The improved knowledge of the molecular basis of the disease because of the discovery of the V617F mutation in the JAK2 gene has improved the molecular diagnosis and opened new avenues to molecular-targeted therapies.
  • [MeSH-minor] Adult. Aged. Aspirin / administration & dosage. Aspirin / therapeutic use. Child. Diagnosis, Differential. Drug Therapy, Combination. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Follow-Up Studies. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / therapeutic use. Immunologic Factors / administration & dosage. Immunologic Factors / therapeutic use. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Male. Mutation. Platelet Aggregation Inhibitors / administration & dosage. Platelet Aggregation Inhibitors / therapeutic use. Platelet Count. Pregnancy. Pregnancy Complications, Hematologic. Primary Prevention. Prospective Studies. Quinazolines / administration & dosage. Quinazolines / therapeutic use. Randomized Controlled Trials as Topic. Risk Assessment. Risk Factors. Time Factors

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896569.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Platelet Aggregation Inhibitors; 0 / Quinazolines; 0 / anagrelide; R16CO5Y76E / Aspirin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 45
  •  go-up   go-down


96. Beer PA, Green AR: Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program; 2009;:621-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The last four years have seen an explosion in our understanding of the myeloproliferative neoplasms.
  • Important and often unexpected insights into the molecular mechanisms responsible for these disorders have been accompanied by the development of new diagnostic tests and by an improved understanding of the relationship between the different disease entities.
  • This review will focus on recent developments in the pathogenesis and management of essential thrombocythemia with a particular emphasis on its phenotypic overlap with polycythemia vera and primary myelofibrosis.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008247.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / anagrelide; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; R16CO5Y76E / Aspirin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 41
  •  go-up   go-down


97. Hsiao HH, Ito Y, Sashida G, Ohyashiki JH, Ohyashiki K: De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk Res; 2005 Nov;29(11):1247-52
Genetic Alliance. consumer health - Essential Thrombocythemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukemic transformation or myelofibrosis is a major concern in managing patients with chronic myeloproliferative disorders, including essential thrombocythemia (ET).
  • We analyze the relationship between cytogenetic changes and the transformation in 89 patients with ET; 8 patients experienced transformation, including 2 patients with acute leukemia following myelofibrosis, 3 with acute leukemia, and 3 with myelofibrosis.
  • Among the eight patients showing transformation, two patients developing myelofibrosis derived from a group with normal cytogenetics, but the remaining six were categorized as showing de novo appearance of cytogenetic changes.
  • Two leukemia patients had de novo cytogenetic changes at the time of leukemia diagnosis, whereas two patients with acute leukemia following myelofibrosis showed der(1;7) during their myelofibrosis period.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 7 / genetics. Leukemia, Myeloid / genetics. Primary Myelofibrosis / genetics. Thrombocythemia, Essential / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Cytogenetic Analysis. Disease Progression. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164981.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L, Mattii L, Battolla B, Capodanno A, Collecchi P, Veroni F, Simi P, Piaggi S, Casini A, Petrini M: PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res; 2008 Jan;32(1):103-12
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because a spontaneous NF-kappaB activation has been reported in megakaryocytes from patients affected by myeloproliferative disorders, Bortezomib would so be an attractive therapeutic tool for these malignancies, including essential thrombocythemia or idiopathic myelofibrosis.
  • Finally, also down-regulation of the WT1 gene Bortezomib-driven could be relevant, because of the role that this gene would play in the pathogenesis of acute and chronic myeloproliferative disorders.
  • [MeSH-minor] Apoptosis. Bortezomib. Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Gene Expression. Genes, Wilms Tumor. Humans. Leukemia, Megakaryoblastic, Acute. Primary Myelofibrosis / metabolism. Primary Myelofibrosis / pathology. Protease Inhibitors / pharmacology. Protein-Serine-Threonine Kinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629554.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.25 / NF-kappa B kinase
  •  go-up   go-down


99. Bernardini P, Giannandrea F, Voso MT, Sica S: [Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases]. Med Lav; 2005 Mar-Apr;96(2):119-25
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases].
  • OBJECTIVES: To describe three recent cases of severe haematological disease presumably induced by an occupational exposure to benzene.
  • METHODS: Clinical diagnosis was performed using standard immuno-phenotypic and morphological criteria; the hypothesis of an occupational origin was derived from analysis of the occupational histories.
  • RESULTS: The first case was a 59 year-old blacksmith suffering from acute myeloid leukaemia (AML) FAB M2, who had used petrol for 36 years to degrease the forged metal parts before painting them.
  • The third was an 82 year-old car mechanic suffering from idiopathic myelofibrosis since the age of 75, who had used petrol to degrease mechanical car motor parts for 42 years.
  • Latency of the disease was between 30-50 years from start of exposure, and between 3-17 years following cessation of exposure.
  • If it cannot, how many cases of benzene-related diseases escape aetiological diagnosis?
  • Furthermore, in all cases of haematological disease potentially related to benzene, any form of contact with petrol, even if uncommon, should be carefully researched.
  • [MeSH-major] Gasoline / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Promyelocytic, Acute / chemically induced. Metallurgy. Motor Vehicles. Occupational Diseases / chemically induced. Primary Myelofibrosis / chemically induced. Solvents / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Alleles. Cytochrome P-450 CYP1A1 / analysis. Cytochrome P-450 CYP1A1 / genetics. Genetic Predisposition to Disease. Glutathione Transferase / analysis. Guideline Adherence. Humans. Inhalation Exposure. Italy / epidemiology. Male. Middle Aged. Occupational Health. Suction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Lav. 2005 Sep-Oct;96(5):447-51 [16711648.001]
  • [ErratumIn] Med Lav. 2005 Sep-Oct;96(5):418
  • (PMID = 16001511.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gasoline; 0 / Solvents; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 2.5.1.18 / glutathione transferase T1-1, human
  •  go-up   go-down


100. Zahnd R, Oestmann A, Ebnöther M: [Lymphadenopathy and diabetes insipidus - association]. Praxis (Bern 1994); 2010 Mar 17;99(6):381-4
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 62 year old women with chronic idiopathic myelofibrosis who developed acute lymphadenopathy.
  • [MeSH-major] Diabetes Insipidus / diagnosis. Histiocytosis, Langerhans-Cell / diagnosis. Lymphatic Diseases / diagnosis. Primary Myelofibrosis / diagnosis






Advertisement